AUTHOR INDEX TO VOLUME 59

Abdelmessih S. *See* Donovan-Lepore A-M
Able JA, Gudelsky GA, Vorhees CV, Williams MT. 3,4-Methylenedioxymethamphetamine in Adult Rats Produces Deficits in Path Integration and Spatial Reference Memory, 1219
Abrous DN. *See* Lemaire V
Ackl N. *See* Post A
Adalsteinsson E. *See* Pfefferbaum A
Adams JM. *See* Joffe H
Adler LA. *See* Wilens TE
Adli M, Bauer M, Rush AJ. Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why? A Systematic Review, 1029
Aftab M. *See* Bueller JA
Akechi T. *See* Yoshikawa E
Akil H. *See* Turner CA
Akiskal HS. *See* Masi G
Akizuki N. *See* Yoshikawa E
Akkerhuis GW. *See* Knijff EM
Alda M. *See* de Lara CL
Aleardi M. *See* Biederman J
Alexander M. *See* Munro CA
Alfonso J, Frick LR, Silberman DM, Palumbo ML, Genaro AM, Frasch AC. Regulation of Hippocampal Gene Expression Is Conserved in Two Species Subjected to Different Stressors and Antidepressant Treatments, 244
Allison N. *See* Taylor FB
Alm PO. *See* Nilsson KW
Almeida OFX. *See* Oliveira M; Post A
Altamirano AV. *See* Gould GG
Amato D. *See* Fava M
Andreasen NC. *See* Paulsen JS
Anisman H. *See* Merali Z
Appelhof BC, Huyser J, Verweij M, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJG, Tijssen JGP, Wiersinga WM, Schene AH. Glucocorticoids and Relapse of Major Depression (Dexamethasone/Corticotropin-Releasing Hormone Test in Relation to Relapse of Major Depression), 696
Arai M. *See* Horiuchi Y
Arai M, Yamada K, Toyota T, Obata N, Haga S, Yoshida Y, Nakamura K, Minabe Y, Ujike H, Sora I, Ikeda K, Mori N, Yoshikawa T, Itokawa M. Association Between Polymorphisms in the Promoter Region of the Sialyltransferase 8B (*SIAT8B*) Gene and Schizophrenia, 652
Arango V. *See* Oquendo MA; Parsey RV; Parsey RV
Arbeitman L. *See* Smoller JW
Archer GE. *See* Leon AC
Archibald DG. *See* Leon AC
Arinami T. *See* Horiuchi Y
Asai K. *See* Koeda M
Åsberg M. *See* Gizatullin R
Assaf M, Rivkin PR, Kuzu CH, Calhoun VD, Kraut MA, Groth KM, Yassa MA, Hart Jr. J, Pearlson GD. Abnormal Object Recall and Anterior Cingulate Overactivation Correlate with Formal Thought Disorder in Schizophrenia, 452
Auther A. *See* Lencz T
Avery DH, Holtzheimer III PE, Fawaz W, Russo J, Neumaier J, Dunner DL, Haynor DR, Claypoole KH, Wajdik C, Roy-Byrne P. A Controlled Study of Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Major Depression, 187
Axelson DA. *See* Forbes EE
Baas JM. *See* Hermans EJ
Baas JMP, Milstein J, Donlevy M, Grillon C. Brainstem Correlates of Defensive States in Humans, 588
Badacsonyi A. *See* Puri V
Bailer UF. *See* Wagner A
Bajbouj M, Lisanby SH, Lang UE, Danker-Hopfe H, Heuser I, Neu P. Evidence for Impaired Cortical Inhibition in Patients with Unipolar Major Depression, 395
Bajpai LK. *See* Bruijnzeel AW
Baldeweg T. *See* Stephan KE
Baldwin RM. *See* Staley JK
Ball W. *See* Keller M
Banasr M, Soumier A, Hery M, Mocaër E, Daszuta A. Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis, 1087
Banerjee SP. *See* MacMaster FP
Bansal R. *See* Blumberg HP
Barbon A, Popoli M, La Via L, Moraschi S, Vallini I, Tardito D, Tiraboschi E, Musazzi L, Giambelli R, Gennarelli M, Racagni G, Barlati S. Regulation of Editing and Expression of Glutamate α-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs, 713
Barlati S. *See* Barbon A
Bass N. *See* Puri V
Bates JA. *See* Umbricht DSG
Bauer M. *See* Adli M
Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee H-J. Chronic Carbamazepine Decreases the Incorporation Rate and Turnover of Arachidonic Acid but Not Docosahexaenoic Acid in Brain Phospholipids of the Unanesthetized Rat: Relevance to Bipolar Disorder, 401
Beckmann K. *See* Quednow BB
Beebe K. *See* Keller M
Begleiter H. *See* Kamarajan C
Belkind D. *See* Cohen H
Beltz TG. *See* Grippo AJ
Bender A. *See* Rujescu D
Benkelfat C. *See* Berney A; de Lara CL
Bens S. *See* Kahl KG
Berardi L. *See* Cornwell BR
Berman RM. *See* Staley JK
Berney A, Sookman D, Leyton M, Young SN, Benkelfat C. Lack of Effects on Core Obsessive-Compulsive Symptoms of Tryptophan Depletion During Symptom Provocation in Remitted Obsessive-Compulsive Disorder Patients, 853
Berns SM. *See* Donovan-Lepore A-M
Bernstein IH. *See* Rush AJ
Bertini N. *See* Masi G
Berton O. *See* Gemelli T
Bessa JM. *See* Oliveira M
Bhandari R. *See* MacMaster FP
Biederman J. *See* Smoller JW
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder, 829
Biederman J, Monuteaux MC, Mick E, Wilens TE, Fontanella JA, Poetzl KM, Kirk T, Masse J, Faraone SV. Is Cigarette Smoking a Gateway to Alcohol and Illicit Drug Use Disorders? A Study of Youths with and without Attention Deficit Hyperactivity Disorder, 258

0006-3223/06/$32.00
doi:10.1016/S0006-3223(06)00715-3

BIOL PSYCHIATRY 2006;59:1248–1259

© 2006 Society of Biological Psychiatry

Biggs MM. *See* Rush AJ
Binder EB. *See* Post A; van Rossum EFC
Birmaher B. *See* Forbes EE
Bisbrown-Chippendale R. *See* Chen C-H
Bisogno T. *See* Tzavara ET
Blackburn J. *See* Morgan CJA
Blendy JA. The Role of CREB in Depression and Antidepressant Treatment, 1144
Bliesener N. *See* Quednow BB
Bliss J. *See* Rayman M
Blumberg HP, Krystal JH, Bansal R, Martin A, Dziura J, Durkin K, Martin L, Gerard E, Charney DS, Peterson BS. Age, Rapid-Cycling, and Pharmacotherapy Effects on Ventral Prefrontal Cortex in Bipolar Disorder: A Cross-Sectional Study, 611
Boon CJ. *See* Sankoorikal GMV
Boucher M. *See* Wann BP
Boutros NN. *See* D'Souza DC
Boyce A. *See* Mostofsky SH
Boyd C. *See* MacMaster FP
Braff DL. *See* Hsieh MH
Brainard GC. *See* Glickman G
Brambilla P. *See* Caetano SC
Brand S. *See* Yehuda R
Brandner B. *See* Morgan CJA
Brasic J. *See* Munro CA
Braw Y. *See* Malkesman O
Breitmeyer B. *See* Green MF
Brett C. *See* Whyte M-C
Brodkin ES. *See* Sankoorikal GMV
Brooks DJ, Piccini P. Imaging in Parkinson's Disease: The Role of Monoamines in Behavior, 908
Brouwer JP. *See* Appelhof BC
Bruijnzeel AW, Lewis B, Bajpai LK, Morey TE, Dennis DM, Gold M. Severe Deficit in Brain Reward Function Associated with Fentanyl Withdrawal in Rats, 477
Bryant R. *See* Cohen RA
Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta J-K. BDNF *Val*^{66}*Met* Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects, 812
Buffalari DM. *See* Rosenkranz JA
Bullmore E. *See* Chen C-H
Burmeister M. *See* Bueller JA
Bédard T. *See* Merali Z
Byrne B. *See* Glickman G
Byrne M. *See* Whyte M-C

Caetano SC, Kaur S, Brambilla P, Nicoletti M, Hatch JP, Sassi RB, Mallinger AG, Keshavan MS, Kupfer DJ, Frank E, Soares JC. Smaller Cingulate Volumes in Unipolar Depressed Patients, 702
Cai L. *See* Nichols L
Cairo TA, Woodward TS, Ngan ETC. Decreased Encoding Efficiency in Schizophrenia, 740
Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR. Recurrence in Bipolar I Disorder: A Post Hoc Analysis Excluding Relapses in Two Double-blind Maintenance Studies, 1061
Calder A. *See* Chen C-H
Calhoun VD. *See* Assaf M
Campo P. *See* Mulas F
Capilla A. *See* Mulas F
Carlezon, Jr. and William A. *See* Chartoff EH
Carlezon, Jr. WA. *See* Nestler EJ, and Carlezon, Jr. WA.
Carlier IVE. *See* Lindauer RJL
Carlino AR. *See* Vasa RA
Carmody TJ. *See* Rush AJ
Caron J. *See* Fava M
Carvalho A. *See* Oliveira M
Castellanos FX. *See* Mulas F
Catterick J. *See* Rayman M
Cavanagh J, Patterson J, Pimlott S, Dewar D, Eersels J, Dempsey MF, Wyper D. Serotonin Transporter Residual Availability During Long-Term Antidepressant Therapy Does Not Differentiate Responder and Nonresponder Unipolar Patients, 301
Cerasa A. *See* Passamonti L
Cercignani M. *See* Flügel D
Cerqueira JJ. *See* Oliveira M
Champagne FA, Meaney MJ. Stress During Gestation Alters Postpartum Maternal Care and the Development of the Offspring in a Rodent Model, 1227
Chang L. *See* Bazinet RP
Chang Y-C. *See* Tsai GE
Charney D. *See* Staley JK
Charney DS. *See* Blumberg HP
Chartier K. *See* Leon AC
Chartoff EH, Pliakas AM, Carlezon, Jr. and William A.. Microinjection of the L-Type Calcium Channel Antagonist Diltiazem into the Ventral Nucleus Accumbens Shell Facilitates Cocaine-Induced Conditioned Place Preferences, 1236
Chawky N. *See* de Lara CL
Chen C-H, Lennox B, Jacob R, Calder A, Lupson V, Bisbrown-Chippendale R, Suckling J, Bullmore E. Explicit and Implicit Facial Affect Recognition in Manic and Depressed States of Bipolar Disorder: A Functional Magnetic Resonance Imaging Study, 31
Chen J, Lipska BK, Weinberger DR. Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models, 1180
Chen W. *See* Zhao X
Chez M. *See* Connolly AM
Chitnis XA. *See* Cutter WJ
Chong M-Y. *See* Tsai GE
Choong K-C. *See* Shen R-Y, and Choong K-C.
Chorlian D. *See* Kamarajan C
Choudhury K. *See* Puri V
Christensen BK. *See* Keefe RSE
Chuang-Stein C. *See* Leon AC
Clark CR. *See* Cohen RA
Claypoole KH. *See* Avery DH
Clines DC. *See* Zisook S
Cohen H, Zohar J, Gidron Y, Matar MA, Belkind D, Loewenthal U, Kozlovsky N, Kaplan Z. Blunted HPA Axis Response to Stress Influences Susceptibility to Posttraumatic Stress Response in Rats, 1208
Cohen LS. *See* Joffe H
Cohen RA, Grieve S, Hoth KF, Paul RH, Sweet L, Tate D, Gunstad J, Stroud L, McCaffery J, Hitsman B, Niaura R, Clark CR, MacFarlane A, Bryant R, Gordon E, Williams LM. Early Life Stress and Morphometry of the Adult Anterior Cingulate Cortex and Caudate Nuclei, 975
Collier DA. *See* Cutter WJ
Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG, Neuman RJ, Deuel

RMK. Brain-Derived Neurotrophic Factor and Autoantibodies to Neural Antigens in Sera of Children with Autistic Spectrum Disorders, Landau-Kleffner Syndrome, and Epilepsy, 354
Conway GS. *See* Cutter WJ
Cooper T. *See* D'Souza DC
Cooper TB. *See* Parsey RV
Coric V. *See* Mason GF
Cornblatt BA. *See* Lencz T
Cornwell BR, Johnson L, Berardi L, Grillon C. Anticipation of Public Speaking in Virtual Reality Reveals a Relationship Between Trait Social Anxiety and Startle Reactivity, 664
Cowen PJ. *See* Harmer CJ
Craig M. *See* Cutter WJ
Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function, 898
Curran HV. *See* Morgan CJA
Curtis D. *See* Puri V
Cutter WJ, Daly EM, Robertson DMW, Chitnis XA, van Amelsvoort TAMJ, Simmons A, Ng VWK, Williams BS, Shaw P, Conway GS, Skuse DH, Collier DA, Craig M, Murphy DGM. Influence of X Chromosome and Hormones on Human Brain Development: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study of Turner Syndrome, 273
Czobor P. *See* Donovan-Lepore A-M

Dahl RE. *See* Forbes EE
Daly E. *See* Schmitz N
Daly EM. *See* Cutter WJ
Damberg M. *See* Nilsson KW
Danker-Hopfe H. *See* Bajbouj M
Daszuta A. *See* Banasr M
Datta S. *See* Puri V
Davies N. *See* Picchioni MM
Day NE. *See* Surtees PG
De Bellis MD. *See* Tupler LA, and De Bellis MD.
de Graaf RA. *See* Mason GF
de Lara CL, Dumais A, Rouleau G, Lesage A, Dumont M, Chawky N, Alda M, Benkelfat C, Turecki G. STin2 Variant and Family History of Suicide as Significant Predictors of Suicide Completion in Major Depression, 114
de Wit HJ. *See* Knijff EM
Deckersbach T, Dougherty DD, Savage C, McMurrich S, Fischman AJ, Nierenberg A, Sachs G, Rauch SL. Impaired Recruitment of the Dorsolateral Prefrontal Cortex and Hippocampus During Encoding in Bipolar Disorder, 138
Dempsey MF. *See* Cavanagh J
Denckla MB. *See* Mostofsky SH
Dennis DM. *See* Bruijnzeel AW
Deuel RMK. *See* Connolly AM
Deurwaerdère PD. *See* Navailles S
DeVane CL. *See* Loughhead AM
DeVeaugh-Geiss A. *See* Calabrese JR
Dewar D. *See* Cavanagh J
Dibbelt L. *See* Kahl KG
Donahue L. *See* D'Souza DC
Donlevy M. *See* Baas JMP
Donovan-Lepore A-M, Jaeger J, Czobor P, Abdelmessih S, Berns SM. Quantitative Craniofacial Anomalies in a Racially Mixed Schizophrenia Sample, 349
Dougherty DD. *See* Deckersbach T
Dougherty M. *See* Biederman J
Douglas-Palumberi H. *See* Kaufman J
Doyle AE. *See* Smoller JW
Doyle R. *See* Biederman J
Drabant EM. *See* Hariri AR
Dranovsky A, Hen R. Hippocampal Neurogenesis: Regulation by Stress and Antidepressants, 1136
Drexhage HA. *See* Knijff EM
D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH. γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation, 128
Du L. *See* Merali Z
Dumais A. *See* de Lara CL
Duman CH. *See* Simen BB
Duman RS. *See* Simen BB
Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders, 1116
Dumont M. *See* de Lara CL
Dunkel S. *See* Biederman J
Dunner DL. *See* Avery DH
Durkin K. *See* Blumberg HP
Dziura J. *See* Blumberg HP

Ebersole JS. *See* D'Souza DC
Eersels J. *See* Cavanagh J
Einat H, Manji HK. Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder, 1160
Ekstrand J. *See* Wennström M
Elgh E, Lindqvist Åstot A, Fagerlund M, Eriksson S, Olsson T, Näsman B. Cognitive Dysfunction, Hippocampal Atrophy and Glucocorticoid Feedback in Alzheimer's Disease, 155
Eliez S. *See* Woodward SH
Elin RJ. *See* Khine K
Ellis SP. *See* Oquendo MA
Epperson CN. *See* Mason GF
Eriksson S. *See* Elgh E
Etchepareborda MC. *See* Mulas F
Evans SJ. *See* Turner CA

Fagerlund M. *See* Elgh E
Fagerness J. *See* Smoller JW
Faludi G. *See* Merali Z
Faraone SV. *See* Biederman J; Smoller JW
Fasula MK. *See* Sanacora G
Fava M. *See* Rush AJ
Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder, 1052
Fawaz W. *See* Avery DH
Feng G. *See* Zhao X
Fenton LR. *See* Sanacora G
Fera F. *See* Passamonti L
Fernández A. *See* Mulas F
Fernández S. *See* Mulas F
Fink GR. *See* Konrad K
Fischman AJ. *See* Deckersbach T
Fitzgerald DA. *See* Phan KL
Fliers E. *See* Appelhof BC
Flint J. *See* Surtees PG

Flügel D, Cercignani M, Symms MR, Koepp MJ, Foong J. A Magnetization Transfer Imaging Study in Patients with Temporal Lobe Epilepsy and Interictal Psychosis, 560
Fontanella JA. *See* Biederman J
Foong J. *See* Flügel D
Forbes EE, Williamson DE, Ryan ND, Birmaher B, Axelson DA, Dahl RE. Peri-Sleep-Onset Cortisol Levels in Children and Adolescents with Affective Disorders, 24
Frank E. *See* Caetano SC
Frank GK. *See* Wagner A
Frasch AC. *See* Alfonso J
Frazer A. *See* Gould GG
Freedman R. *See* Tanabe J
Frick LR. *See* Alfonso J
Friston KJ. *See* Stephan KE
Frye M. *See* Calabrese JR
Fuchs C. *See* Poyurovsky M
Fujimori M. *See* Yoshikawa E
Fujita M. *See* Cropley VL
Funato H. *See* Matsubara T

Galassini R. *See* Rayman M
Gallo O. *See* Passamonti L
Gelernter J. *See* Kaufman J
Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM. Postnatal Loss of Methyl-CpG Binding Protein 2 in the Forebrain is Sufficient to Mediate Behavioral Aspects of Rett Syndrome in Mice, 468
Genaro AM. *See* Alfonso J
Genius J. *See* Rujescu D
Gennarelli M. *See* Barbon A
Gerard E. *See* Blumberg HP
Gerig G. *See* Hazlett HC
Gersons BPR. *See* Lindauer RJL
Giambelli R. *See* Barbon A
Gidron Y. *See* Cohen H
Giegling I. *See* Rujescu D
Gil RB. *See* D'Souza DC
Gillman PK. A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action, 1046
Ginovart N. *See* Willeit M
Gioia MC. *See* Passamonti L
Giros B. *See* Tzavara ET
Gizatullin R, Zaboli G, Jönsson EG, Åsberg M, Leopardi R. Haplotype Analysis Reveals Tryptophan Hydroxylase (TPH) 1 Gene Variants Associated with Major Depression, 295
Glickman G, Byrne B, Pineda C, Hauck WW, Brainard GC. Light Therapy for Seasonal Affective Disorder with Blue Narrow-Band Light-Emitting Diodes (LEDs), 502
Godbout R. *See* Wann BP
Gold M. *See* Bruijnzeel AW
Goldberg JF. *See* Calabrese JR
Goldberg MC. *See* Mostofsky SH
Golumbek PT. *See* Connolly AM
Gomez-Hassan D. *See* Bueller JA
Goodwin GM. *See* Harmer CJ
Gordon E. *See* Cohen RA
Gould GG, Altamirano AV, Javors MA, Frazer A. A Comparison of the Chronic Treatment Effects of Venlafaxine and Other Antidepressants on Serotonin and Norepinephrine Transporters, 408
Grace AA. *See* Rosenkranz JA
Grasso D. *See* Kaufman J
Green MF, Nuechterlein KH, Breitmeyer B, Mintz J. Forward and Backward Visual Masking in Unaffected Siblings of Schizophrenic Patients, 446
Greer P. *See* Wagner A
Grieve S. *See* Cohen RA
Grillon C. *See* Baas JMP; Cornwell BR
Grippo AJ, Beltz TG, Weiss RM, Johnson AK. The Effects of Chronic Fluoxetine Treatment on Chronic Mild Stress-Induced Cardiovascular Changes and Anhedonia, 309
Groth KM. *See* Assaf M
Grunze H. *See* Rujescu D
Gudelsky GA. *See* Able JA
Gueorguieva R. *See* Mason GF
Guidone E. *See* Mason GF
Gunstad J. *See* Cohen RA
Gurling HMD. *See* Puri V

Haberstick BC, Smolen A, Hewitt JK. Family-Based Association Test of the 5HTTLPR and Aggressive Behavior in a General Population Sample of Children, 836
Haga S. *See* Arai M
Haight BR. *See* Zisook S
Halbach OB, Krause S, Medina D, Sciarretta C, Minichiello L, Unsicker K. Regional- and Age-Dependent Reduction in trkB Receptor Expression in the Hippocampus Is Associated with Altered Spine Morphologies, 793
Hall E. *See* Rayman M
Hall JE. *See* Joffe H
Hamer RM. *See* Keefe RSE
Hammerness P. *See* Biederman J
Hanisch C. *See* Konrad K
Hargreaves R. *See* Keller M
Hariri AR, Drabant EM, Weinberger DR. Imaging Genetics: Perspectives from Studies of Genetically Driven Variation in Serotonin Function and Corticolimbic Affective Processing, 888
Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues, 816
Harpold T. *See* Biederman J
Harrison LK. *See* Whyte M-C
Hart Jr. J. *See* Assaf M
Hartmann AM. *See* Rujescu D
Hashimoto K. *See* Ozawa K
Hatch JP. *See* Caetano SC
Hauck WW. *See* Glickman G
Haynor DR. *See* Avery DH
Hazlett HC, Poe MD, Gerig G, Smith RG, Piven J. Cortical Gray and White Brain Tissue Volume in Adolescents and Adults with Autism, 1
He L. *See* Zhao X
Hellsten J. *See* Wennström M
Hen R. *See* Dranovsky A, and Hen R.
Henry SE. *See* Wagner A
Herbert J. *See* Huang G-J, and Herbert J.
Hermans EJ, Putman P, Baas JM, Koppeschaar HP, Honk J. A Single Administration of Testosterone Reduces Fear-Potentiated Startle in Humans, 872
Herpertz-Dahlmann B. *See* Konrad K
Hery M. *See* Banasr M
Heuser I. *See* Bajbouj M
Hewitt JK. *See* Haberstick BC
Hietala J. *See* Keller M

Higuchi M. *See* Takahashi H
Hitsman B. *See* Cohen RA
Hoge EA. *See* Pollack MH
Hoge J. *See* Wagner A
Holsboer F. *See* Müller MB, and Holsboer F.; Post A; van Rossum EFC
Holtzheimer III PE. *See* Avery DH
Honk J. *See* Hermans EJ
Hoogendijk WJG. *See* Appelhof BC
Horiuchi Y, Arai M, Niizato K, Iritani S, Noguchi E, Ohtsuki T, Koga M, Kato T, Itokawa M, Arinami T. A Polymorphism in the PDLIM5 Gene Associated with Gene Expression and Schizophrenia, 434
Hoth KF. *See* Cohen RA
Houle S. *See* Willeit M
Houshyar S. *See* Kaufman J
Hovey L. *See* Lencz T
Hrdina P. *See* Merali Z
Hsieh MH, Swerdlow NR, Braff DL. Effects of Background and Prepulse Characteristics on Prepulse Inhibition and Facilitation: Implications for Neuropsychiatric Research, 555
Huang G-J, Herbert J. Stimulation of Neurogenesis in the Hippocampus of the Adult Rat by Fluoxetine Requires Rhythmic Change in Corticosterone, 619
Huang Y. *See* Parsey RV
Hussey D. *See* Willeit M
Huyser J. *See* Appelhof BC
Hwang CH. *See* Joffe H

Ikeda K. *See* Arai M
Imoto S. *See* Yoshikawa E
Inagaki M. *See* Yoshikawa E
Innis RB. *See* Cropley VL; Nichols L; Staley JK
Iritani S. *See* Horiuchi Y
Ishikura H. *See* Ozawa K
Ising M. *See* Post A; van Rossum EFC
Itokawa M. *See* Arai M; Horiuchi Y
Ivey J. *See* MacMaster FP
Iyo M. *See* Ozawa K

Jackson ED, Payne JD, Nadel L, Jacobs WJ. Stress Differentially Modulates Fear Conditioning in Healthy Men and Women, 516
Jacob R. *See* Chen C-H
Jacobs WJ. *See* Jackson ED
Jaeger J. *See* Donovan-Lepore A-M
Jaenisch R. *See* Gemelli T
Javitt DC. *See* Umbricht DSG
Javors MA. *See* Gould GG
Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS. Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder, 1078
Johnson AK. *See* Grippo AJ
Johnson L. *See* Cornwell BR
Johnstone EC. *See* Whyte M-C
Jones K. *See* Kamarajan C
Jönsson EG. *See* Gizatullin R

Kaercher KA. *See* Sankoorikal GMV
Kahl KG, Bens S, Ziegler K, Rudolf S, Dibbelt L, Kordon A, Schweiger U. Cortisol, the Cortisol-Dehydroepiandrosterone Ratio, and Pro-Inflammatory Cytokines in Patients with Current Major Depressive Disorder Comorbid with Borderline Personality Disorder, 667
Kahn RS. *See* Raemaekers M
Kaloupek DG. *See* Woodward SH
Kaloustian S. *See* Wann BP
Kamarajan C, Porjesz B, Jones K, Chorlian D, Padmanabhapillai A, Rangaswamy M, Stimus A, Begleiter H. Event-Related Oscillations in Offspring of Alcoholics: Neurocognitive Disinhibition as a Risk for Alcoholism, 625
Kamei H, Nagai T, Nakano H, Togan Y, Takayanagi M, Takahashi K, Kobayashi K, Yoshida S, Maeda K, Takuma K, Nabeshima T, Yamada K. Repeated Methamphetamine Treatment Impairs Recognition Memory Through a Failure of Novelty-Induced ERK1/2 Activation in the Prefrontal Cortex of Mice, 75
Kamiya A. *See* Paek KIM
Kandasami G. *See* Puri V
Kane JM. *See* Umbricht DSG
Kanter ED. *See* Taylor FB
Kaplan Z. *See* Cohen H
Kapur S. *See* Willeit M
Kasai K. *See* Yoshikawa E
Kassir SA. *See* Oquendo MA
Kato T. *See* Horiuchi Y
Kaufman J, Yang B-Z, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, Gelernter J. Brain-Derived Neurotrophic Factor–5-HTTLPR Gene Interactions and Environmental Modifiers of Depression in Children, 673
Kaur S. *See* Caetano SC
Kaye WH. *See* Wagner A
Keck M. *See* Rujescu D
Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman, for the HGDH Research Group JA. Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis, 97
Keeling RM. *See* Connolly AM
Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin$_1$ Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder, 216
Kelly K. *See* Puri V
Kent JM. *See* Parsey RV
Kent P. *See* Merali Z
Kerwin S. *See* Puri V
Keshavan MS. *See* Caetano SC; MacMaster FP
Kesner Y. *See* Malkesman O
Ketter TA. *See* Calabrese JR
Khine K, Rosenstein DL, Elin RJ, Niemela JE, Schmidt PJ, Rubinow DR. Magnesium (Mg) Retention and Mood Effects After Intravenous Mg Infusion in Premenstrual Dysphoric Disorder, 327
Kinrys G. *See* Pollack MH
Kirk T. *See* Biederman J
Kishimoto T. *See* Ozawa K
Knijff EM, Ruwhof C, de Wit HJ, Kupka RW, Vonk R, Akkerhuis GW, Nolen WA, Drexhage HA. Monocyte-Derived Dendritic Cells in Bipolar Disorder, 317
Kobayakawa M. *See* Yoshikawa E
Kobayashi A. *See* Matsubara T
Kobayashi K. *See* Kamei H
Koeda M, Takahashi H, Yahata N, Matsuura M, Asai K, Okubo

Y, Tanaka H. Language Processing and Human Voice Perception in Schizophrenia: A Functional Magnetic Resonance Imaging Study, 948
Koepp MJ. *See* Flügel D
Koga M. *See* Horiuchi Y
Köhler S. *See* Wagner G
Konrad K, Neufang S, Hanisch C, Fink GR, Herpertz-Dahlmann B. Dysfunctional Attentional Networks in Children with Attention Deficit/Hyperactivity Disorder: Evidence from an Event-Related Functional Magnetic Resonance Imaging Study, 643
Koper JW. *See* van Rossum EFC
Koppeschaar HP. *See* Hermans EJ
Kordon A. *See* Kahl KG
Kozlovsky N. *See* Cohen H
Kraemer HC, Kupfer DJ. Size of Treatment Effects and Their Importance to Clinical Research and Practice, 990
Krasucki R. *See* Puri V
Krause S. *See* Halbach OB
Kraut MA. *See* Assaf M
Krystal A. *See* Fava M
Krystal JH. *See* Blumberg HP; D'Souza DC; Kaufman J; Mason GF; Sanacora G
Kugaya A. *See* Staley JK
Kühn K-U. *See* Quednow BB
Kumar A. *See* Munro CA
Kupfer DJ. *See* Caetano SC; Kraemer HC, and Kupfer DJ.
Kupka RW. *See* Knijff EM
Kurosaki M, Shirao N, Yamashita H, Okamoto Y, Yamawaki S. Distorted Images of One's Own Body Activates the Prefrontal Cortex and Limbic/Paralimbic System in Young Women: A Functional Magnetic Resonance Imaging Study, 380
Kuwabara H. *See* Munro CA
Kuzu CH. *See* Assaf M
Kwon JM. *See* Connolly AM

La Via L. *See* Barbon A
Lamarque S. *See* Lemaire V
Lamb G. *See* Puri V
Lamberts SWJ. *See* van Rossum EFC
Landau S. *See* Picchioni MM
Lang UE. *See* Bajbouj M
Lavori P. *See* Joffe H
Lavori PW. *See* Sackeim HA
Lawrence D. *See* Rayman M
Lawrence J. *See* Puri V
Lawrie SM. *See* Whyte M-C
Lee H-J. *See* Bazinet RP
Lee JK. *See* Sankoorikal GMV
Lemaire V, Lamarque S, Moal ML, Piazza P-V, Abrous DN. Postnatal Stimulation of the Pups Counteracts Prenatal Stress-Induced Deficits in Hippocampal Neurogenesis, 786
Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA. Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia, 863
Lennox B. *See* Chen C-H
Leon AC. *See* Wisniewski SR
Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology, 1001
Leopardi R. *See* Gizatullin R
Leppert J. *See* Nilsson KW
Lesage A. *See* de Lara CL
Levin Y. *See* Sanacora G
Lewis B. *See* Bruijnzeel AW
Leyton M. *See* Berney A
Li DL. *See* Tzavara ET
Li H. *See* Zhao X
Li K. *See* Seto B
Lieberman, for the HGDH Research Group JA. *See* Keefe RSE
Lieberman JA. *See* Umbricht DSG
Lindauer RJL, Olff M, Meijel EP, Carlier IVE, Gersons BPR. Cortisol, Learning, Memory, and Attention in Relation to Smaller Hippocampal Volume in Police Officers with Posttraumatic Stress Disorder, 171
Lindgren H. *See* Wennström M
Lindqvist Åstot A. *See* Elgh E
Lindsay E. *See* Paylor R, and Lindsay E.
Lindström L. *See* Nilsson KW
Lines C. *See* Keller M
Lipschitz D. *See* Kaufman J
Lipska BK. *See* Chen J
Lisanby SH. *See* Bajbouj M
Liu G. *See* Keller M
Liu H. *See* Zhao X
Liu J. *See* Zhao X
Loewenthal U. *See* Cohen H
Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental Passage of Tricyclic Antidepressants, 287
Lowe K. *See* Taylor FB
Luben R. *See* Surtees PG
Lupson V. *See* Chen C-H
Lynch M. *See* MacMaster FP

Maayan R. *See* Malkesman O
MacDougall LM. *See* D'Souza DC
MacFarlane A. *See* Cohen RA
Maciejewski PK. *See* Staley JK
Mackay CE. *See* Harmer CJ
MacMaster FP, Russell A, Mirza Y, Keshavan MS, Banerjee SP, Bhandari R, Boyd C, Lynch M, Rose M, Ivey J, Moore GJ, Rosenberg DR. Pituitary Volume in Pediatric Obsessive-Compulsive Disorder, 252
Maeda K. *See* Kamei H
Maestú F. *See* Mulas F
Magariello A. *See* Passamonti L
Magnotta VA. *See* Paulsen JS
Maier W. *See* Quednow BB
Majer M. *See* van Rossum EFC
Malison RT. *See* Staley JK
Malkesman O, Braw Y, Maayan R, Weizman A, Overstreet DH, Shabat-Simon M, Kesner Y, Touati-Werner D, Yadid G, Weller A. Two Different Putative Genetic Animal Models of Childhood Depression, 17
Mallinckrodt CH. *See* Leon AC
Mallinger AG. *See* Caetano SC
Manji HK. *See* Einat H, and Manji HK.; Zarate, Jr., CA
Mann JJ. *See* Oquendo MA; Parsey RV; Parsey RV
Marinou V. *See* Wagner G
Martin A. *See* Blumberg HP
Martin L. *See* Blumberg HP
Martin LF. *See* Tanabe J
Martin P. *See* Taylor FB

Martinez C. *See* Woodward SH
Martín AB. *See* Pavón N
Marzo VD. *See* Tzavara ET
Masi G, Perugi G, Toni C, Millepiedi S, Mucci M, Bertini N, Akiskal HS. The Clinical Phenotypes of Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic-Distinction, 603
Mason GF. *See* Sanacora G
Mason GF, Petrakis IL, de Graaf RA, Gueorguieva R, Guidone E, Coric V, Epperson CN, Rothman DL, Krystal JH. Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking, 85
Masse J. *See* Biederman J
Matar MA. *See* Cohen H
Matsubara T, Funato H, Kobayashi A, Nobumoto M, Watanabe Y. Reduced Glucocorticoid Receptor α Expression in Mood Disorder Patients and First-Degree Relatives, 689
Matsuoka Y. *See* Yoshikawa E
Matsuura M. *See* Koeda M
McCaffery J. *See* Cohen RA
McCall WV. *See* Fava M
McCarley RW. *See* Rujescu D
McCaul ME. *See* Munro CA
McConaha C. *See* Wagner A
McFall MM. *See* Taylor FB
McLaughlin A. *See* Seto B
McLaughlin D. *See* Lencz T
McLaughlin WL. *See* Joffe H
McMurrich S. *See* Deckersbach T
McQuillin A. *See* Puri V
Meaney MJ. *See* Champagne FA, and Meaney MJ.
Medina D. *See* Halbach OB
Meijel EP. *See* Lindauer RJL
Meltzer CC. *See* Wagner A
Mendialdua A. *See* Pavón N
Menkens A. *See* Seto B
Mentzel H-J. *See* Straube T; Wagner G
Merali Z, Kent P, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Bédard T, Anisman H. Corticotropin-Releasing Hormone, Arginine Vasopressin, Gastrin-Releasing Peptide, and Neuromedin B Alterations in Stress-Relevant Brain Regions of Suicides and Control Subjects, 594
Mesquita A. *See* Oliveira M
Mick E. *See* Biederman J; Biederman J; Pollack MH
Mikos AE. *See* Paulsen JS
Millepiedi S. *See* Masi G
Miller P. *See* Whyte M-C
Milstein J. *See* Baas JMP
Miltner WHR. *See* Straube T
Minabe Y. *See* Arai M
Minichiello L. *See* Halbach OB
Mintz J. *See* Green MF
Mirza Y. *See* MacMaster FP
Miyakawa T. *See* Powell CM, and Miyakawa T.
Moal ML. *See* Lemaire V
Mocaër E. *See* Banasr M
Modell S. *See* van Rossum EFC
Möller H-J. *See* Rujescu D
Monteggia LM. *See* Duman RS, and Monteggia LM.; Gemelli T
Montgomery S. *See* Keller M
Monuteaux MC. *See* Biederman J
Moore GJ. *See* MacMaster FP
Moorey H. *See* Puri V
Moraschi S. *See* Barbon A
Moratalla R. *See* Pavón N
Morey TE. *See* Bruijnzeel AW
Morgan CJA, Rossell SL, Pepper F, Smart J, Blackburn J, Brandner B, Curran HV. Semantic Priming after Ketamine Acutely in Healthy Volunteers and Following Chronic Self-Administration in Substance Users, 265
Morgan J. *See* Puri V
Mori N. *See* Arai M
Morrison M. *See* Keller M
Mostofsky SH, Rimrodt SL, Schafer JGB, Boyce A, Goldberg MC, Pekar JJ, Denckla MB. Atypical Motor and Sensory Cortex Activation in Attention-Deficit/Hyperactivity Disorder: A Functional Magnetic Resonance Imaging Study of Simple Sequential Finger Tapping, 48
Moutsimilli L. *See* Tzavara ET
Mucci M. *See* Masi G
Muglia M. *See* Passamonti L
Mulas F, Capilla A, Fernández S, Etchepareborda MC, Campo P, Maestú F, Fernández A, Castellanos FX, Ortiz T. Shifting-Related Brain Magnetic Activity in Attention-Deficit/Hyperactivity Disorder, 373
Müller MB, Holsboer F. Mice with Mutations in the HPA-System as Models for Symptoms of Depression, 1104
Mundt JC. *See* Rush AJ
Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS. Sex Differences in Striatal Dopamine Release in Healthy Adults, 958
Murakami K. *See* Yoshikawa E
Murck H, Spitznagel H, Ploch M, Seibel K, Schaffler K. Hypericum Extract Reverses S-Ketamine-Induced Changes in Auditory Evoked Potentials in Humans – Possible Implications for the Treatment of Schizophrenia, 440
Murphy DGM. *See* Cutter WJ; Schmitz N
Murray RM. *See* Picchioni MM
Musazzi L. *See* Barbon A

Nabeshima T. *See* Kamei H
Nadeem H. *See* Puri V
Nadel L. *See* Jackson ED
Nagai T. *See* Kamei H
Nakamura K. *See* Arai M
Nakano H. *See* Kamei H
Nakano T. *See* Yoshikawa E
Nakaya N. *See* Yoshikawa E
Nakayama E. *See* Lencz T
Näsman B. *See* Elgh E
Nathan PJ. *See* Cropley VL; Phan KL
Navailles S, Deurwaerdère PD, Spampinato U. Clozapine and Haloperidol Differentially Alter the Constitutive Activity of Central Serotonin$_{2C}$ Receptors In Vivo, 568
Nelson ED. *See* Gemelli T
Nestler EJ. Special Issue: Animal Models of Mood and Psychotic Disorders, 1103
Nestler EJ, Carlezon, Jr. WA. The Mesolimbic Dopamine Reward Circuit in Depression, 1151
Neu P. *See* Bajbouj M
Neufang S. *See* Konrad K
Neumaier J. *See* Avery DH
Neuman RJ. *See* Connolly AM
Newport DJ. *See* Loughhead AM

Ng VWK. *See* Cutter WJ
Ngan ETC. *See* Cairo TA
Niaura R. *See* Cohen RA
Nichols L, Pike VW, Cai L, Innis RB. Imaging and In Vivo Quantitation of β-Amyloid: An Exemplary Biomarker for Alzheimer's Disease?, 940
Nicoletti G. *See* Passamonti L
Nicoletti M. *See* Caetano SC
Niemela JE. *See* Khine K
Nierenberg A. *See* Deckersbach T
Nierenberg AA. *See* Rush AJ
Niizato K. *See* Horiuchi Y
Nilsson KW, Sjöberg RL, Damberg M, Leppert J, Öhrvik J, Alm PO, Lindström L, Oreland L. Role of Monoamine Oxidase A Genotype and Psychosocial Factors in Male Adolescent Criminal Activity, 121
Nim S. *See* Wann BP
Nobumoto M. *See* Matsubara T
Noguchi E. *See* Horiuchi Y
Nolen WA. *See* Knijff EM
Nomikos GG. *See* Tzavara ET
Nopoulos PC. *See* Paulsen JS
Nuechterlein KH. *See* Green MF

Obata N. *See* Arai M
Ogden RT. *See* Parsey RV
Ohl F. *See* Rujescu D
Öhrvik J. *See* Nilsson KW
Ohtsuki T. *See* Horiuchi Y
Okamoto Y. *See* Kurosaki M
Okubo Y. *See* Koeda M
Olff M. *See* Lindauer RJL
Oliveira M, Bessa JM, Mesquita A, Tavares H, Carvalho A, Silva R, Pêgo JM, Cerqueira JJ, Palha JA, Almeida OFX, Sousa N. Induction of a Hyperanxious State by Antenatal Dexamethasone: A Case for Less Detrimental Natural Corticosteroids, 844
Olsson T. *See* Elgh E
Olvet DM. *See* Parsey RV
Oppenheimer J. *See* Pollack MH
Oquendo MA. *See* Parsey RV; Parsey RV
Oquendo MA, Russo SA, Underwood MD, Kassir SA, Ellis SP, Mann JJ, Arango V. Higher Postmortem Prefrontal 5-HT_{2A} Receptor Binding Correlates with Lifetime Aggression in Suicide, 235
Oreland L. *See* Nilsson KW
Ortiz T. *See* Mulas F
Oswald LM. *See* Munro CA
Otto MW. *See* Wisniewski SR
Overstreet DH. *See* Malkesman O
Owens MJ. *See* Loughhead AM
Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune Activation During Pregnancy in Mice Leads to Dopaminergic Hyperfunction and Cognitive Impairment in the Offspring: A Neurodevelopmental Animal Model of Schizophrenia, 546

Padmanabhapillai A. *See* Kamarajan C
Paek KIM, Kamiya A, Sawa A. A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions, 1189
Palha JA. *See* Oliveira M
Palkovits M. *See* Merali Z
Palumbo ML. *See* Alfonso J
Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper TB, Arango V, Mann JJ. Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [^{11}C]DASB and Positron Emission Tomography, 821
Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang Y, Van Heertum RL, Arango V, Mann JJ. Altered Serotonin 1A Binding in Major Depression: A [carbonyl-C-11]WAY100635 Positron Emission Tomography Study, 106
Pashinian A. *See* Poyurovsky M
Passamonti L, Fera F, Magariello A, Cerasa A, Gioia MC, Muglia M, Nicoletti G, Gallo O, Provinciali L, Quattrone A. Monoamine Oxidase-A Genetic Variations Influence Brain Activity Associated with Inhibitory Control: New Insight into the Neural Correlates of Impulsivity, 334
Patterson J. *See* Cavanagh J
Paul RH. *See* Cohen RA
Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC. Brain Structure in Preclinical Huntington's Disease, 57
Paulson HL. *See* Paulsen JS
Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice, 64
Paylor R, Lindsay E. Mouse Models of 22q11 Deletion Syndrome, 1172
Payne JD. *See* Jackson ED
Pearlson GD. *See* Assaf M
Pekar JJ. *See* Mostofsky SH
Penziner E. *See* Paulsen JS
Pepper F. *See* Morgan CJA
Perlis RH. *See* Smoller JW
Perrotti LI. *See* Gemelli T
Perugi G. *See* Masi G
Peskind ER. *See* Taylor FB
Peterson BS. *See* Blumberg HP
Petrakis IL. *See* Mason GF
Pettigrew R. *See* Seto B
Pfefferbaum A, Adalsteinsson E, Sullivan EV. Supratentorial Profile of White Matter Microstructural Integrity in Recovering Alcoholic Men and Women, 364
Phan KL, Fitzgerald DA, Nathan PJ, Tancer ME. Association between Amygdala Hyperactivity to Harsh Faces and Severity of Social Anxiety in Generalized Social Phobia, 424
Phebus LA. *See* Tzavara ET
Piazza P-V. *See* Lemaire V
Picchioni MM, Toulopoulou T, Landau S, Davies N, Ribchester T, Murray RM. Neurological Abnormalities in Schizophrenic Twins, 341
Piccini P. *See* Brooks DJ, and Piccini P.
Pike VW. *See* Nichols L
Pimlott S. *See* Cavanagh J
Pimm J. *See* Puri V
Pine DS. *See* Vasa RA
Pineda C. *See* Glickman G
Piven J. *See* Hazlett HC
Pliakas AM. *See* Chartoff EH
Ploch M. *See* Murck H
Poe MD. *See* Hazlett HC
Poetzl KM. *See* Biederman J
Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine

Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study, 211
Popoli M. *See* Barbon A
Porjesz B. *See* Kamarajan C
Post A, Ackl N, Rücker M, Schreiber Y, Binder EB, Ising M, Sonntag A, Holsboer F, Almeida OFX. Toward a Reliable Distinction Between Patients with Mild Cognitive Impairment and Alzheimer-Type Dementia Versus Major Depression, 858
Poulter MO. *See* Merali Z
Powell CM, Miyakawa T. Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?, 1198
Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial, 1071
Pratap M. *See* Parsey RV
Provinciali L. *See* Passamonti L
Punukollu B. *See* Puri V
Puri V, McQuillin A, Thirumalai S, Lawrence J, Krasucki R, Choudhury K, Datta S, Kerwin S, Quested D, Bass N, Pimm J, Lamb G, Moorey H, Kandasami G, Badacsonyi A, Kelly K, Morgan J, Punukollu B, Nadeem H, Curtis D, Gurling HMD. Failure to Confirm Allelic Association Between Markers at the CAPON Gene Locus and Schizophrenia in a British Sample, 195
Putman P. *See* Hermans EJ
Putnam K. *See* Wagner A
Pêgo JM. *See* Oliveira M

Quattrone A. *See* Passamonti L
Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn K-U. Sensorimotor Gating and Habituation of the Startle Response in Schizophrenic Patients Randomly Treated With Amisulpride or Olanzapine, 536
Quested D. *See* Puri V

Racagni G. *See* Barbon A
Raeder H. *See* Rujescu D
Raemaekers M, Ramsey NF, Vink M, van den Heuvel MP, Kahn RS. Brain Activation During Antisaccades in Unaffected Relatives of Schizophrenic Patients, 530
Ramsey NF. *See* Raemaekers M
Rangaswamy M. *See* Kamarajan C
Rao JS. *See* Bazinet RP
Rapoport SI. *See* Bazinet RP
Raskind MA. *See* Taylor FB
Rauch SL. *See* Deckersbach T
Rayman M, Thompson A, Warren-Perry M, Galassini R, Catterick J, Hall E, Lawrence D, Bliss J. Impact of Selenium on Mood and Quality of Life: A Randomized, Controlled Trial, 147
Reid CB. *See* Harmer CJ
Reines S. *See* Keller M
Ribchester T. *See* Picchioni MM
Richards MC. *See* Parsey RV
Rimrodt SL. *See* Mostofsky SH
Ritchie JC. *See* Loughhead AM
Riviello JJ. *See* Connolly AM
Rivkin PR. *See* Assaf M
Robertson DMW. *See* Cutter WJ
Robinson RG. *See* Connolly AM
Rock SL. *See* Keefe RSE
Rockett CB. *See* Zisook S
Roose SP. *See* Sackeim HA
Rose M. *See* MacMaster FP
Rosenberg DR. *See* MacMaster FP
Rosenkranz JA, Buffalari DM, Grace AA. Opposing Influence of Basolateral Amygdala and Footshock Stimulation on Neurons of the Central Amygdala, 801
Rosenstein DL. *See* Khine K
Rossell SL. *See* Morgan CJA
Roth T. *See* Fava M
Rothman DL. *See* Mason GF; Sanacora G
Rouleau G. *See* de Lara CL
Rousseau G. *See* Wann BP
Roy-Byrne P. *See* Avery DH
Rubens R. *See* Fava M
Rubia K. *See* Schmitz N
Rubinow DR. *See* Khine K
Rücker M. *See* Post A
Rudolf S. *See* Kahl KG
Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Möller H-J, Grunze H. A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities, 721
Rush AJ. Special Issue on Therapeutics, 989
Rush AJ. *See* Adli M; Zisook S
Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M. An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report, 493
Russell A. *See* MacMaster FP
Russo J. *See* Avery DH
Russo SA. *See* Oquendo MA
Ruwhof C. *See* Knijff EM
Ryan ND. *See* Forbes EE

Sachs G. *See* Deckersbach T
Sachs GS. *See* Joffe H
Sackeim HA, Roose SP, Lavori PW. Determining the Duration of Antidepressant Treatment: Application of Signal Detection Methodology and the Need for Duration Adaptive Designs (DAD), 483
Salyakina D. *See* van Rossum EFC
Sanacora G. *See* Staley JK
Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF. Cortical γ-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy, 284
Sanger TM. *See* Keefe RSE
Sankoorikal GMV, Kaercher KA, Boon CJ, Lee JK, Brodkin ES. A Mouse Model System for Genetic Analysis of Sociability: C57BL/6J Versus BALB/cJ Inbred Mouse Strains, 415
Sassi RB. *See* Caetano SC
Sauer H. *See* Wagner G
Savage C. *See* Deckersbach T
Sawa A. *See* Paek KIM
Schaer M. *See* Woodward SH
Schafer JGB. *See* Mostofsky SH
Schaffler K. *See* Murck H

Schene AH. *See* Appelhof BC
Schlösser RGM. *See* Wagner G
Schmidt PJ. *See* Khine K
Schmitz N, Rubia K, Daly E, Smith A, Williams S, Murphy DGM. Neural Correlates of Executive Function in Autistic Spectrum Disorders, 7
Schreiber Y. *See* Post A
Schweiger U. *See* Kahl KG
Sciarretta C. *See* Halbach OB
Scolnick EM. Mechanisms of Action of Medicines for Schizophrenia and Bipolar Illness: Status and Limitations, 1039
Seeman P. *See* Willeit M
Seibel K. *See* Murck H
Seibyl J. *See* D'Souza DC
Seibyl JP. *See* Staley JK
Seidman LJ. *See* Keefe RSE
Sen S. *See* Bueller JA
Seto B, McLaughlin A, Li K, Menkens A, Sullivan D, Pettigrew R. Advancing the Boundaries of Molecular Imaging, 881
Shabat-Simon M. *See* Malkesman O
Sharma T. *See* Keefe RSE
Shaw P. *See* Cutter WJ
Shen J. ^{13}C Magnetic Resonance Spectroscopy Studies of Alterations in Glutamate Neurotransmission, 883
Shen R-Y, Choong K-C. Different Adaptations in Ventral Tegmental Area Dopamine Neurons in Control and Ethanol Exposed Rats After Methylphenidate Treatment, 635
Shi J. *See* Zhao X
Shi Y. *See* Zhao X
Shimizu E. *See* Ozawa K
Shirao N. *See* Kurosaki M
Shores-Wilson K. *See* Rush AJ
Silberman DM. *See* Alfonso J
Silva R. *See* Oliveira M
Simen AA. *See* Simen BB
Simen BB, Duman CH, Simen AA, Duman RS. TNFα Signaling in Depression and Anxiety: Behavioral Consequences of Individual Receptor Targeting, 775
Simmons A. *See* Cutter WJ .
Simon NM. *See* Pollack MH
Simpson N. *See* Parsey RV .
Singh J. *See* Zarate, Jr., CA
Sinsel E. *See* Wagner G
Sitskoorn MM. *See* Keefe RSE
Sjöberg RL. *See* Nilsson KW
Sklar P. *See* Smoller JW
Skuse DH. *See* Cutter WJ
Smart J. *See* Morgan CJA
Smith A. *See* Schmitz N
Smith CW. *See* Lencz T
Smith RG. *See* Hazlett HC
Smolen A. *See* Haberstick BC
Smoller JW, Biederman J, Arbeitman L, Doyle AE, Fagerness J, Perlis RH, Sklar P, Faraone SV. Association Between the 5HT1B Receptor Gene (*HTR1B*) and the Inattentive Subtype of ADHD, 460
Snavely D. *See* Keller M
Soares JC. *See* Caetano SC
Sobanski T. *See* Wagner G
Sonntag A. *See* Post A
Sookman D. *See* Berney A
Sora I. *See* Arai M
Soumier A. *See* Banasr M
Sousa N. *See* Oliveira M
Spampinato U. *See* Navailles S
Spencer T. *See* Biederman J
Spitznagel H. *See* Murck H
Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB. Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression, 40
Stephan KE, Baldeweg T, Friston KJ. Synaptic Plasticity and Dysconnection in Schizophrenia, 929
Stimus A. *See* Kamarajan C
Stowe ZN. *See* Loughhead AM
Straube T, Mentzel H-J, Miltner WHR. Neural Mechanisms of Automatic and Direct Processing of Phobogenic Stimuli in Specific Phobia, 162
Streeter CC. *See* Woodward SH
Streif EM. *See* Connolly AM
Stroud L. *See* Cohen RA
Suckling J. *See* Chen C-H
Suhara T. *See* Takahashi H
Sullivan D. *See* Seto B
Sullivan EV. *See* Pfefferbaum A
Suppes T. *See* Calabrese JR; Joffe H
Surman C. *See* Biederman J
Surtees PG, Wainwright NW, Willis-Owen SA, Luben R, Day NE, Flint J. Social Adversity, the Serotonin Transporter (5-HTTLPR) Polymorphism and Major Depressive Disorder, 224
Sweet L. *See* Cohen RA
Swerdlow NR. *See* Hsieh MH
Symms MR. *See* Flügel D

Takahashi H. *See* Koeda M
Takahashi H, Higuchi M, Suhara T. The Role of Extrastriatal Dopamine D2 Receptors in Schizophrenia, 919
Takahashi K. *See* Kamei H
Takayanagi M. *See* Kamei H
Takuma K. *See* Kamei H
Tamagnan G. *See* Staley JK
Tanabe J, Tregellas JR, Martin LF, Freedman R. Effects of Nicotine on Hippocampal and Cingulate Activity During Smooth Pursuit Eye Movement in Schizophrenia, 754
Tanaka H. *See* Koeda M
Tancer ME. *See* Phan KL
Tang R. *See* Zhao X
Tardito D. *See* Barbon A
Tate D. *See* Cohen RA
Tavares H. *See* Oliveira M
Taylor FB, Lowe K, Thompson C, McFall MM, Peskind ER, Kanter ED, Allison N, Williams J, Martin P, Raskind MA. Daytime Prazosin Reduces Psychological Distress to Trauma Specific Cues in Civilian Trauma Posttraumatic Stress Disorder, 577
Thirumalai S. *See* Puri V
Thompson A. *See* Rayman M
Thompson C. *See* Taylor FB
Thompson TR. *See* Calabrese JR
Tijssen JGP. *See* Appelhof BC
Tingström A. *See* Wennström M
Tiraboschi E. *See* Barbon A
Togan Y. *See* Kamei H

Tohen M. *See* Keefe RSE
Tollefson GD. *See* Keefe RSE
Toni C. *See* Masi G
Touati-Werner D. *See* Malkesman O
Toulopoulou T. *See* Picchioni MM
Toyota T. *See* Arai M
Tregellas JR. *See* Tanabe J
Trivedi MH. *See* Rush AJ; Wisniewski SR
Tsai GE, Yang P, Chang Y-C, Chong M-Y. D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia, 230
Tupler LA, De Bellis MD. Segmented Hippocampal Volume in Children and Adolescents with Posttraumatic Stress Disorder, 523
Turecki G. *See* de Lara CL
Turner CA, Akil H, Watson SJ, Evans SJ. The Fibroblast Growth Factor System and Mood Disorders, 1128
Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Marzo VD, Phebus LA, Nomikos GG, Giros B. Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications, 508

Uchitomi Y. *See* Yoshikawa E
Ujike H. *See* Arai M
Umbricht DSG, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia, 762
Underwood MD. *See* Oquendo MA
Unsicker K. *See* Halbach OB

Vallini I. *See* Barbon A
van Amelsvoort TAMJ. *See* Cutter WJ
van den Heuvel MP. *See* Raemaekers M
van Dyck R. *See* Appelhof BC
Van Heertum RL. *See* Parsey RV
van Rossum EFC, Binder EB, Majer M, Koper JW, Ising M, Modell S, Salyakina D, Lamberts SWJ, Holsboer F. Polymorphisms of the Glucocorticoid Receptor Gene and Major Depression, 681
Vasa RA, Carlino AR, Pine DS. Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions, 1021
Verlinden MH. *See* Wilens TE
Verweij M. *See* Appelhof BC
Vink M. *See* Raemaekers M
Vonk R. *See* Knijff EM
Vorhees CV. *See* Able JA
Vythilingam M. *See* Staley JK

Wagner A, Greer P, Bailer UF, Frank GK, Henry SE, Putnam K, Meltzer CC, Ziolko SK, Hoge J, McConaha C, Kaye WH. Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia Nervosa, 291
Wagner G, Sinsel E, Sobanski T, Köhler S, Marinou V, Mentzel H-J, Sauer H, Schlösser RGM. Cortical Inefficiency in Patients with Unipolar Depression: An Event-Related fMRI Study with the Stroop Task, 958
Wagner M. *See* Quednow BB
Wainwright NW. *See* Surtees PG
Wajdik C. *See* Avery DH
Wand GS. *See* Munro CA
Wann BP, Boucher M, Kaloustian S, Nim S, Godbout R, Rousseau G. Apoptosis Detected in the Amygdala Following Myocardial Infarction in the Rat, 430
Warren-Perry M. *See* Rayman M
Watanabe Y. *See* Matsubara T
Watson SJ. *See* Turner CA
Weinberger DR. *See* Chen J; Hariri AR
Weiss RM. *See* Grippo AJ
Weizman A. *See* Malkesman O; Poyurovsky M
Weizman R. *See* Poyurovsky M
Weller A. *See* Malkesman O
Wennström M, Hellsten J, Ekstrand J, Lindgren H, Tingström A. Corticosterone-Induced Inhibition of Gliogenesis in Rat Hippocampus is Counteracted by Electroconvulsive Seizures, 178
Wessel T. *See* Fava M
West SA. *See* Wilens TE
Westheide J. *See* Quednow BB
White R. *See* Calabrese JR
Whyte M-C, Brett C, Harrison LK, Byrne M, Miller P, Lawrie SM, Johnstone EC. Neuropsychological Performance Over Time in People at High Risk of Developing Schizophrenia and Controls, 730
Wiersinga WM. *See* Appelhof BC
Wilens TE. *See* Biederman J
Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA. ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study, 1065
Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA. High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [^{11}C]-(+)-PHNO, 389
Williams BS. *See* Cutter WJ
Williams J. *See* Taylor FB
Williams LM. *See* Cohen RA
Williams MT. *See* Able JA
Williams S. *See* Schmitz N
Williamson DE. *See* Forbes EE
Willis-Owen SA. *See* Surtees PG
Wilson AA. *See* Willeit M
Wisniewski S. *See* Rush AJ
Wisniewski SR, Leon AC, Otto MW, Trivedi MH. Prevention of Missing Data in Clinical Research Studies, 997
Wong DF. *See* Munro CA
Woo A. *See* Rush AJ
Woodward SH, Kaloupek DG, Streeter CC, Martinez C, Schaer M, Eliez S. Decreased Anterior Cingulate Volume in Combat-Related PTSD, 582
Woodward TS. *See* Cairo TA
Woolson S. *See* Keefe RSE
Worthington JJ. *See* Pollack MH
Wozniak PJ. *See* Wilens TE
Wyper D. *See* Cavanagh J

Yadid G. *See* Malkesman O
Yahata N. *See* Koeda M
Yamada K. *See* Arai M; Kamei H
Yamashita H. *See* Kurosaki M
Yamasue H. *See* Yoshikawa E
Yamawaki S. *See* Kurosaki M
Yan L. *See* Zhao X
Yang B-Z. *See* Kaufman J
Yang P. *See* Tsai GE

Yang R-K. *See* Yehuda R
Yassa MA. *See* Assaf M
Ye W. *See* Munro CA
Yehuda R, Brand S, Yang R-K. Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping, 660
Yoshida S. *See* Kamei H
Yoshida Y. *See* Arai M
Yoshikawa E, Matsuoka Y, Yamasue H, Inagaki M, Nakano T, Akechi T, Kobayakawa M, Fujimori M, Nakaya N, Akizuki N, Imoto S, Murakami K, Kasai K, Uchitomi Y. Prefrontal Cortex and Amygdala Volume in First Minor or Major Depressive Episode After Cancer Diagnosis, 707
Yoshikawa T. *See* Arai M
Young SN. *See* Berney A

Zaboli G. *See* Gizatullin R
Zalta AK. *See* Pollack MH
Zarate, Jr., CA, Singh J, Manji HK. Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder, 1006
Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J, Feng G, Shi J, Yan L, Liu H, He L. Significant Association Between the Genetic Variations in the 5′ End of the N-Methyl-D-Aspartate Receptor Subunit Gene *GRIN1* and Schizophrenia, 747
Zhou Y. *See* Munro CA
Ziegler K. *See* Kahl KG
Ziolko SK. *See* Wagner A
Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of Bupropion in Combination with Serotonin Reuptake Inhibitors, 203
Zohar J. *See* Cohen H
Zubieta J-K. *See* Bueller JA
Zuzarte E. *See* D'Souza DC

SUBJECT INDEX TO VOLUME 59

ABT-089, 1065
Acoustic startle response
  schizophrenia-related habituation of, 536
Adolescents
  affective disorders in, peri-sleep-onset cortisol levels in, 24
  bipolar disorder in
    chronic vs. episodic, 603
    ventral prefrontal cortex declines, 611
  cigarette smoking as gateway to alcohol and drug abuse in, 258
  criminal behavior in
    monoamine oxidase A genotype's role in, 121
    psychosocial factors associated with, 121
  depression in, pharmacotherapy for, 1021
  posttraumatic stress disorder in, segmented hippocampal volume in, 523
Affective disorders
  peri-sleep-onset cortisol levels in, 24
Aggression
  5-HT_{2A} receptor binding and, in suicide, 235
  5-HTTLPR gene and, family-based association test of, 836
Agomelatine, 1087
Akathisia, antipsychotic-induced, 1071
Alcohol abuse
  cigarette smoking as gateway to, in attention-deficit/hyperactivity disorder youth, 258
Alcoholics
  event-related oscillations in offspring of, 625
Alcoholism
  neurocognitive disinhibition as risk for, 625
  white matter deficits in, supratentorial profile in, 364
Algorithms, for depression, 1029
Alzheimer's disease
  β-amyloid peptide in, 940
  biomarkers in, 940
  cognitive dysfunction in, 155
  dementia, mild cognitive impairment differentiated from, 858
  glucocorticoid feedback in, 155
  hippocampal atrophy in, 155
  limbic-hypothalamic-pituitary-adrenal axis in, 155
á-Amino-propionic-acid receptors, 713
Amisulpride, 536
Amygdala
  apoptosis detection in, after myocardial infarction, 430
  basolateral, 801
  central, 801
  footshock stimulation effects on, 801
  hyperactivity of, social anxiety in generalized social phobia, 424
  neurons of, 801
  volume of, in major depression after cancer diagnosis, 707
ß-Amyloid peptide, 940
Anhedonia
  fluoxetine effects on, 309
Animal models
  of bipolar disorder, 1160
  of childhood depression, 17
  of mood disorders, 1103
Anorexia nervosa
  brain tissue volumes after long-term recovery from, 291
Anterior cingulate
  morphometry, early life stress effects on, 975
  overaction of, formal thought disorder in schizophrenia and, 452
  volume of, in combat-related posttraumatic stress disorder, 582
Antidepressants
  agomelatine, 1087
  α-amino-propionic-acid receptor expression, 713
  cyclic adenosine monophosphate response element binding protein's role in, 1144
  duration adaptive designs, 483
  glucocorticoid receptor gene polymorphisms' effect on, 681
  glutamate receptor expression, 713
  hippocampal neurogenesis regulated by, 1136
  mechanism of action, 1046
  neurogenesis stimulated in hippocampus by, 619
  serotonin transporter residual availability during therapy with, 301
  suicidality and, 1021
  threat-relevant cue neural processing modified by, 816
  transcranial magnetic stimulation-produced results with similarities to, 187
  treatment duration for, 483
  venlafaxine effects on, 408
Antipsychotics
  acoustic startle response habituation and, 536
  akathisia induced by, 1071
  D-alanine added to, for schizophrenia, 230
  neurocognitive effects of, in first-episode psychosis, 97
  prepulse inhibition affected by, 536
  startle reactivity affected by, 536
Anxiety
  brainstem correlates of, 588
  dexamethasone effects on, 844
  tumor necrosis factor-α signaling in, 775
Apoptosis in amygdala after myocardial infarction, 430
Aprepitant, 216
Arachidonic acid
  carbamazepine effects on incorporation rate of, in brain phospholipids, 401
Arginine vasopressin
  in suicide victims, 594
Attentional dysfunction, 643
Attention-deficit/hyperactivity disorder
  ABT-089 for, 1065
  attentional dysfunction in, 643
  cigarette smoking as gateway to alcohol and illicit drug use in, 258
  frontal–striatal circuits in, 373
  hyperdopaminergia-related hyperactivity, endocannabinoids' effect on, 508
  inattentive subtype of, 5HT1B receptor gene and, 460
  methylphenidate for
    OROS, 829
    ventral tegmental area dopamine neurons affected by, 635
  motor cortex activation in, 48
  sensory cortex activation in, 48
  shifting-related brain magnetic activity in, 373
Attrition, in randomized clinical trials, 1001
Auditory evoked potentials

0006-3223/06/$32.00
doi:10.1016/S0006-3223(06)00717-7

BIOL PSYCHIATRY 2006;59:1260–1267

© 2006 Society of Biological Psychiatry

ketamine-induced changes in, hypericum extract reversal of, 440
Auditory information processing, in schizophrenia, 762
Autism, 1
Autistic spectrum disorders
brain-derived neurotrophic factor autoantibodies in, 354
executive function in, neural correlates of, 7
neural antigen autoantibodies in, 354
Autoantibodies
in autistic spectrum disorders, 354
in childhood disintegrative disorder, 354
Automatic information processing, in schizophrenia, 762

Backward masking, 446
Basolateral amygdala, 801
Bipolar disorder
in adolescents, 603
animal models of, genes-to-behavior pathways in, 1160
in children, 603
cognitive impairments in, 138
depression, facial affect recognition in, 31
drug development for, 1006
encoding in, 138
episodic memory impairment in, 138
genes-to-behavior pathways in, 1160
juvenile, clinical phenotypes of, 603
lamotrigine for, 1061
lithium for, 1061
mania, facial affect recognition in, 31
monocyte-derived dendritic cells in, 317
new-onset oligoamenorrhea and, 1078
novel therapeutics for, 1006
recurrence in, 1061
schizophrenia and, 1039
ventral prefrontal cortex in, age effects on, 611
in women, valproate and, 1078
Blue narrow-band light-emitting diodes, for seasonal affective disorder, 502
Body image distortions
prefrontal cortex activation secondary to, 380
Borderline personality disorder
major depression concomitantly presenting with, 667
Brain
activity of, during antisaccades in unaffected relatives of schizophrenic patients, 530
development of, X chromosome and hormones influence on, 273
phospholipids of, carbamazepine effects on incorporation rate of arachidonic acid in, 401
reward function deficits, caused by fentanyl withdrawal, 477
structure of, in Huntington's disease, 57
Brain tissue volume
after long-term recovery in anorexia and bulimia nervosa, 291
Brain-derived neurotrophic factor
antidepressants and, 1116
autoantibodies, in autistic spectrum disorders, 354
5-HTTLPR gene and, in childhood depression, 673
trkB receptor expression, 793
Val^{66}*met* allele, 812
Brainstem auditory evoked potentials, 588
Bulimia nervosa
brain tissue volumes after long-term recovery from, 291
Bupropion
selective serotonin reuptake inhibitors and, 203
^{13}C magnetic resonance spectroscopy, 883

CAPON gene
schizophrenia and, 195
Carbamazepine
arachidonic acid incorporation rate in brain phospholipids decreased by, 401
Cardiovascular system
chronic mild stress-induced changes in, fluoxetine's effects on, 309
Caudate nuclei
early life stress effects on morphometry of, 975
CDC-like kinase 1, 244
Cellular plasticity cascades, 1006, 1160
Central amygdala, 801
Child abuse, 673
Childhood disintegrative disorder
brain-derived neurotrophic factor autoantibodies, 354
neural antigen autoantibodies in, 354
Children
affective disorders in, peri-sleep-onset cortisol levels in, 24
attentional dysfunction in, 643
bipolar disorder in, 603
depression in
animal models of, 17
brain-derived neurotropic factor–5-HTTLPR gene interactions in, 673
child abuse and, 673
environmental modifiers of, 673
genetic models of, 17
pharmacotherapy for, 1021
obsessive-compulsive disorder in, pituitary volume associated with, 252
posttraumatic stress disorder in, segmented hippocampal volume in, 523
Chromosome 1q23.3, 195
Cigarette smoking
alcohol and illicit drug use and, in attention-deficit/hyperactivity disorder youth, 258
ethanol dependence attenuated by, 85
Cingulate
anterior. *See* Anterior cingulate
nicotine effects on, during smooth pursuit eye movement in schizophrenia, 754
volume of, in unipolar depression, 582
Clozapine
serotonin$_{2C}$ receptor activity affected by, 568
Cocaine, 1236
Cognitive behavioral therapy
cortical gamma-aminobutyric acid levels in patients receiving, for depression, 284
Cognitive dysfunction
in Alzheimer's disease, 155
Cognitive function
dopaminergic system and, 898
Cognitive impairments
in bipolar disorder, 138
immune activation during pregnancy as cause of, in offspring, 546
methamphetamine-induced, 75
mild, versus Alzheimer-type dementia, 858

Collaborative-care systems, for depression, 1029
Combat-related posttraumatic stress disorder
  anterior cingulate volume decreases associated with, 582
  neuropeptide Y concentrations, 660
Confidence intervals, 990
Cortical lobe
  gray tissue of, 1
  impaired inhibition of, in major depression, 395
  white tissue of, 1
Corticolimbic affective processing, 888
Corticosterone
  fluoxetine and, 619
  gliogenesis in hippocampus inhibited by, electroconvulsive seizures' effect on, 178
Corticotropin-releasing hormone
  major depression relapse and, 696
  in suicide victims, 594
Cortisol
  in major depression disorder comorbid with borderline personality disorder, 667
  peri-sleep-onset levels of, in affective disorders, 24
  posttraumatic stress disorder and, 171
Cortisol-dehydroepiandrosterone ratio
  in major depression disorder comorbid with borderline personality disorder, 667
[^{11}C]-(+)-PHNO
  dopamine D2/3 receptor high affinity states imaged using, 389
Craniofacial anomalies
  in schizophrenia, 349
Criminal behavior, adolescent
  monoamine oxidase A genotype's role in, 121
  psychosocial factors associated with, 121
Cyclic adenosine monophosphate response element binding protein, 1144
Cytokines
  in major depression disorder comorbid with borderline personality disorder, 667
  tumor necrosis factor-α, 775

D-alanine, 230
Defensive states
  brainstem correlates of, 588
Dementia, Alzheimer's-disease
  mild cognitive impairment vs., 858
Dendritic cells
  monocyte-derived, in bipolar disorder, 317
Dendritic spines, 793
Depression. *See also* Major depression
  algorithms for, 1029
  in bipolar disorder, facial affect recognition in, 31
  cardiovascular dysfunction and, serotonin's role in, 309
  childhood
    animal models of, 17
    brain-derived neurotropic factor–5-HTTLPR gene interactions in, 673
    child abuse and, 673
    environmental modifiers of, 673
    genetic models of, 17
    pharmacotherapy for, 1021
  cognitive behavioral therapy for, 284
  collaborative-care systems for, 1029
  cortical gamma-aminobutyric acid levels in, 284
  cyclic adenosine monophosphate response element binding protein's role in, 1144
  fibroblast growth factor and, 1128
  Hamilton rating scale for, 493
  hippocampal neurogenesis in, 1136
  mesolimbic dopamine reward circuit in, 1151
  Quick Inventory of Depressive Symptomatology, 493
  tumor necrosis factor-α signaling in, 775
  unipolar
    cingulate volumes in, 702
    cortical inefficiency in, 958
    cortical inhibition impairments in, 395
Dexamethasone/corticotropin-releasing hormone test, 696
Diencephalon serotonin transporter
  in major depression, 40
Disrupted-in-Schizophrenia-1, 1189
Dissociation
  gamma-aminobutyric acid–serotonin interaction in, 128
Docosahexaenoic acid
  carbamazepine effects on incorporation rate of, in brain phospholipids, 401
Dopamine
  mesolimbic, in depression, 1151
  striatal, sex differences in release of, 966
Dopamine D2/3 receptors
  extrastriatal, in schizophrenia, 919
  high affinity states of, imaged by [^{11}C]-(+)-PHNO, 389
Dopaminergic system
  cognitive function and, 898
  hyperfunction of, immune activation during pregnancy as cause of, 546
  molecular imaging of, 898
Duration adaptive designs, for antidepressants, 483
Dyskinesia
  L-DOPA-induced, ERK phosphorylation and FosB expression associated with, 64

Early life stress
  anterior cingulate morphometry affected by, 975
Eating disorders
  brain tissue volumes after long-term recovery from, 291
Effect sizes, 990
Electroconvulsive seizures
  corticosterone-induced inhibition of gliogenesis in hippocampus affected by, 178
Encoding
  in bipolar disorder, 138
  in schizophrenia, 740
Endocannabinoids
  transient receptor potential vanilloid 1 receptors activated by, 508
Epilepsy, temporal lobe
  interictal psychosis and, magnetization transfer imaging study of, 560
Episodic memory impairment
  in bipolar disorder, 138
ER22/23EK polymorphisms, 681
Eszopiclone
  fluoxetine and, in insomnia patients with major depressive disorder, 1052
Ethanol dependence
  cortical gamma-aminobutyric acid levels and recovery from, 85

smoking and, 85
Event-related oscillations
in offspring of alcoholics, 625
Executive function
in autistic spectrum disorder, 7
neural correlates of, 7
Externally regulated kinase phosphorylation
in L-DOPA-induced dyskinesia, 64
Extracellular signal-regulated kinase 1/2
methamphetamine-induced recognition memory impairment caused by, 75
Extrastriatal dopamine D2 receptors, in schizophrenia, 919

Facial affect recognition
in depression, 31
in mania, 31
Fear
antidepressant effects on neural processing of cues related to, 816
brainstem correlates of, 588
of negative evaluation, 664
testosterone effects on, 872
Fear conditioning
stress-induced modulation of, 516
Fear-potentiated startle, 872
Fentanyl withdrawal, 477
Fibroblast growth factor, 1128
Fluoxetine
chronic mild stress-induced cardiovascular changes prevented using, 309
corticosterone and, 619
eszopiclone and, in insomnia patients with major depressive disorder, 1052
neurogenesis stimulated in hippocampus by, 619
olanzapine augmentation of, for refractory generalized anxiety disorder, 211
Footshock, 801
Forebrain
methyl-CpG binding protein 2 postnatal loss in, and Rett syndrome, 468
Formal thought disorder, in schizophrenia, 452
Forward masking, 446
FosB expression
in L-DOPA-induced dyskinesia, 64
Frontal–striatal circuits, in attention-deficit/hyperactivity disorder, 373
Functional magnetic resonance imaging
ADHD uses, 48
cortical inefficiency in unipolar depression studied using, 958
event-related, for studying attentional dysfunction in ADHD children, 643
language processing and human voice perception in schizophrenia studied using, 948
prefrontal cortex and limbic/paralimbic system activation secondary to body image distortions, 380

G protein alpha q polypeptide, 244
Gamma-aminobutyric acid
cortical
in depressed patients receiving cognitive behavioral therapy, 284
ethanol dependence affected by, 85
serotonin and, in psychosis pathophysiology, 128
Gastrin-releasing peptide
in suicide victims, 594
Gender
diencephalon serotonin transporter availability in major depression associated with, 40
prefrontal cortex and limbic/paralimbic system activation secondary to body image distortions based on, 380
striatal dopamine release differences based on, 966
Generalized anxiety disorder
olanzapine augmentation of fluoxetine for, 211
refractory, 211
Generalized social phobia
amygdala hyperactivity to harsh faces correlated with severity of, 424
Gliogenesis
corticosterone-induced inhibition of, electroconvulsive seizures' effect on, 178
Glucocorticoid receptors
corticosterone affinity for, 844
dexamethasone affinity for, 844
gene
expression of, in mood disorder patients, 689
polymorphisms of, in major depression, 681
Glucocorticoids
feedback, in Alzheimer's disease, 155
during pregnancy, 844
Glutamate receptors, 713
Glutamate-glutamine cycle, 883
Glycogen synthase kinase-3, 1006
Gray tissue
cortical, in autism, 1
GRIN1, 747
GRIN2, 747

Haloperidol
neurocognitive effects of, in first-episode psychosis, 97
serotonin$_{2C}$ receptor activity affected by, 568
Hamilton rating scale, 493
Haplotype analysis
of tryptophan hydroxylase 1 gene variants in major depression, 295
Hippocampus
atrophy of, in Alzheimer's disease, 138
dendritic spines, trkB receptor effects on, 793
dentate gyrus of, 619
fluoxetine-induced stimulation of neurogenesis in, 619
gene expression, 244
gliogenesis in, electroconvulsive seizure effects on, 178
impaired recruitment of, in bipolar disorder encoding, 138
neurogenesis
agomelatine-induced regional changes in, 1087
fluoxetine-induced stimulation of, 619
prenatal stress effects on, 786
nicotine effects on, during smooth pursuit eye movement in schizophrenia, 754
in police officers with posttraumatic stress disorder, 171
segmented volume of, in children and adolescents with posttraumatic stress disorder, 523
stress effects on, 244
trkB receptor expression in, 793
ventral, 1087
volume of

brain-derived neurotrophic factor *Val*^{66}*met* allele and, 812
in posttraumatic stress disorder, 171
5-HTTLPR gene
aggressive behavior and, family-based association test of, 836
brain-derived neurotrophic factor and, in childhood depression, 673
variant of, 888
Human voice perception, in schizophrenia, 948
Huntington's disease, 57
Hyperandrogenism, oligoamenorrhea with, 1078
Hypericum extract
ketamine-induced changes in auditory evoked potentials reversed by, 440
Hypothalamic-pituitary-adrenal axis
blunted response of, to stress, 1208
in major depression, 681
in mood disorders, 689
mouse models in, 1104
mutations in, 1104

Illicit drugs
cigarette smoking as gateway to, in attention-deficit/hyperactivity disorder youth, 258
Immune activation during pregnancy
dopaminergic hyperfunction and cognitive impairment in offspring secondary to, 546
Impulsivity
neural correlates of, 334
Insomnia
in major depressive disorder, eszopiclone and fluoxetine for, 1052
Interictal psychosis
temporal lobe epilepsy and, magnetization transfer imaging study of, 560

Juvenile bipolar disorder
clinical phenotypes of, 603

Kainate receptors, 713
Ketamine
auditory evoked potentials changes induced by, hypericum extract reversal of, 440
semantic priming after use of, in substance users, 265

Lamotrigine, for bipolar disorder, 1061
Landau-Kleffner syndrome, 354
Language processing, in schizophrenia, 948
L-DOPA-induced dyskinesia
ERK phosphorylation and FosB expression associated with, 64
Light therapy, for seasonal affective disorder, 502
Limbic-hypothalamic-pituitary-adrenal axis
in Alzheimer's disease, 155
in obsessive-compulsive disorder pathogenesis, 252
Lithium, for bipolar disorder, 1061
L-type calcium channels, 1236

Magnesium
premenstrual dysphoric disorder and, 327
Magnetic resonance imaging
functional. *See* Functional magnetic resonance imaging
Turner syndrome evaluated using, 273
Magnetic resonance spectroscopy
^{13}C, of, glutamate neurotransmission alterations, 883
Turner syndrome evaluated using, 273
Magnetization transfer imaging
in temporal lobe epilepsy patient with interictal psychosis, 560
Major depression. *See also* Depression
Alzheimer's-type dementia vs., 858
amygdala volume in, 707
aprepitant for, 216
borderline personality disorder concomitantly presenting with, 667
after cancer diagnosis, 707
cortical inhibition impairments in, 395
dexamethasone/corticotropin-releasing hormone test and, 696
diencephalon serotonin transporter availability in, 40
glucocorticoid receptor gene polymorphisms and, 681
insomnia in, eszopiclone and fluoxetine for, 1052
medication-resistant, repetitive transcranial magnetic stimulation for, 187
prefrontal cortex volume in, after cancer diagnosis, 707
relapse of, 696
serotonin 1A binding in, 106
social adversity and serotonin transporter polymorphism, 224
suicide completion in
neuropeptide levels assessed after, 594
serotonin receptor intron 2 variant associated with, 114
tryptophan hydroxylase 1 gene variants associated with, haplotype analysis of, 295
unipolar
cingulate volumes in, 702
cortical inefficiency in, 958
cortical inhibition impairments in, 395
Mania, 31
m-chlorophenylpiperazine, 128
MDMA, 1219
Medication-resistant major depression
repetitive transcranial magnetic stimulation for, 187
Membrane glycoprotein 6a, 244
Memory impairment
posttraumatic stress disorder and, 171
Methamphetamine
recognition memory impaired because of, 75
Methyl-CpG binding protein 2
postnatal loss in forebrain correlated with behavioral aspects of Rett syndrome, 468
3,4-Methylenedioxymethamphetamine, 1219
Methylphenidate
OROS, in adults with ADHD, 829
ventral tegmental area dopamine neurons affected by, 635
Mirtazapine, 1046; 1071
Mismatch negativity, 762
MK-801, 721
Moclobemide, 1046
Molecular imaging
description of, 881
of dopaminergic system, 898
Monoamine oxidase inhibitors, 1046
Monoamine oxidase-A
adolescent criminal behavior and, 121

brain activity associated with inhibitory control influenced by genetic variations of, 334
Monoamines, 908
Monocyte-derived dendritic cells
in bipolar disorder, 317
Mood
selenium's effects on, 147
Mood disorders
animal models of, 1103
fibroblast growth factor system and, 1128
glucocorticoid receptor α expression in, 689
stress-related, neurotrophic model for, 1116
Motor cortex
in attention-deficit/hyperactivity disorder, 48
Mouse models
BALB/cJ strain, 415
C57BL/6J strain, 415
for depression, 1104
poly I:C, 546
of schizophrenia, 1180, 1198
sociability studies using, 415
stress during pregnancy, 1227
of 22q11 deletion syndrome, 1172
Myocardial infarction
apoptosis in amygdala caused by, 430

Negative evaluation, fear of, 664
Nerve growth factor, 244
Neural cell adhesion molecule 1, 652
Neurocognition
deficits of, in schizophrenia, 863
haloperidol effects on, 97
olanzapine effects on, 97
Neurogenesis, hippocampal
agomelatine-induced regional changes in, 1087
fluoxetine-induced stimulation of, 619
prenatal stress effects on, 786
stress and, 1136
Neurokinin$_1$ receptor, 216
Neurological abnormalities
in schizophrenia, 341
Neuromedin B
in suicide victims, 594
Neuropeptides
in suicide victims, 594
Y, in posttraumatic stress disorder, 660
Neuropsychological performance, in at-risk schizophrenia patients, 730
Nicotine
cingulate effects of, 754
hippocampal effects of, 754
Nicotinic receptors, 1065
N-methyl-D-aspartate receptors
GRIN1, 747
GRIN2, 747
hypofunction and, in psychosis, 721
subunit genes, 747
Norepinephrine transporter
venlafaxine effects on, 408
Nucleus accumbens shell, 1236

Obsessive-compulsive disorder
pediatric, pituitary volume in, 252
relapse of, 853
tryptophan depletion effects on core symptoms of, 853
Olanzapine
acoustic startle response habituation and, 536
fluoxetine augmented with, for refractory generalized anxiety disorder, 211
neurocognitive effects of, in first-episode psychosis, 97
prepulse inhibition affected by, 536
startle reactivity affected by, 536
Oligoamenorrhea, 1078

Parkinson's disease, 908
PDLIM5 gene polymorphism, 434
Phobia
specific, phobogenic stimuli in, 162
Phobogenic stimuli
in specific phobia, 162
Pituitary gland
volume of, in pediatric obsessive-compulsive disorder, 252
Placenta
tricyclic antidepressant passage across, 287
Plasticity, cellular, 1006, 1160
Polycystic ovarian syndrome, 1078
Positron emission tomography
Parkinson's disease evaluations, 908
sertraline occupancy of serotonin transporter studied using, 821
Posttraumatic stress disorder. *See also* Stress
in adolescents, 523
blunted hypothalamic-pituitary-adrenal axis response and, 1208
in children, 523
civilian, 577
combat-related
anterior cingulate volume decreases associated with, 582
neuropeptide Y concentrations, 660
coping with, 660
cortisol levels and, 171
fear conditioning and, 516
hippocampal volume in, 171, 523
memory impairments and, 171
prazosin for, 577
Prazosin
posttraumatic stress disorder treated with, 577
Prefrontal cortex
extracellular signal-regulated kinase 1/2 activation in, methamphetamine-induced recognition memory impairment as cause of, 75
ventral, in bipolar disorder, 611
volume of, in major depression after cancer diagnosis, 707
Pregnancy
glucocorticoids during, 844
immune activation during, dopaminergic hyperfunction and cognitive impairment in offspring secondary to, 546
stress during, effects on maternal care, 1227
tricyclic antidepressant passage across placenta during, 287
Premenstrual dysphoric disorder
magnesium's role in, 327
Prenatal stress, 786
Prepulse facilitation, 555
Prepulse inhibition, in schizophrenia
antipsychotics' effect on, 536
background noise effects on, 555

prepulse characteristics' effect on, 555
Pro-inflammatory cytokines
in major depression disorder comorbid with borderline personality disorder, 667
Propranolol, 1071
Proton magnetic resonance spectroscopy
Turner syndrome evaluated using, 273
Psychosis
animal models of, 1103
first-episode
haloperidol for, 97
olanzapine for, 97
gamma-aminobutyric acid–serotonin interaction in, 128
interictal, and temporal lobe epilepsy, 560
neurocognitive deficits in schizophrenia as precursor to, 863
N-methyl-D-aspartate receptor hypofunction and, 721
pharmacological model for, 721
Public speaking-related social anxiety, 664

Quality of life
selenium's effects on, 147
Quick Inventory of Depressive Symptomatology, 493

Randomized clinical trials
attrition in, 1001
effect sizes in, 990
Recognition memory
methamphetamine-induced impairment of, 75
Regional cerebral blood flow
abnormalities in, during bipolar disorder encoding, 138
Repetitive transcranial magnetic stimulation
medication-resistant major depression treated with, 187
Research studies
effect sizes, 990
missing data in, 997
Rett syndrome
methyl-CpG binding protein 2 postnatal loss in forebrain and, 468

Schizophrenia
acoustic startle response habituation in, 536
anthropometric studies in, 349
antisaccades in, brain activation during, 530
auditory information processing in, 762
automatic information processing in, 762
backward masking in, 446
behavioral testing in, 1198
bipolar illness and, 1039
CAPON gene and, 195
craniofacial anomalies in, 349
D-alanine added to antipsychotics for, 230
Disrupted-in-Schizophrenia-1, 1189
dopamine D2 receptors in, 919
encoding efficiency in, 740
formal thought disorder in, 452
forward masking in, 446
human voice perception in, 948
hypericum extract for, 440
language processing in, 948
maternal viral infection and, 546
mismatch negativity deficits in, 762
mouse models of, 1180, 1198
neurocognitive deficits in, 863
neurodevelopmental animal model of, 546
neurological abnormalities in, 341
neuropsychological performance in, 730
N-methyl-D-aspartate receptor subunit gene *GRIN1* and, 747
PDLIM5 gene polymorphism and, 434
prepulse inhibition impairments in
antipsychotics effect on, 536
background noise effects on, 555
prepulse characteristics' effect on, 555
sensorimotor gating in, 536
sialyltransferase 8B gene polymorphisms and, 652
siblings of patients with
backward masking in, 446
brain activation during antisaccades in, 530
smooth pursuit eye movement in, nicotine effects on, 754
startle response habituation in, 536
synaptic plasticity in, 929
in twins, 341
visual masking in, 446
Seasonal affective disorder
light therapy for, 502
Selective serotonin reuptake inhibitors
bupropion used with, 203
olanzapine augmentation of, for refractory generalized anxiety disorder, 211
serotonin 1A receptors' effect on, 106
serotonin transporter occupancy by, 821
Selenium
mood affected by, 147
quality of life affected by, 147
Semantic memory
formal thought disorder in schizophrenia and, 452
Semantic priming
after ketamine use in substance users, 265
Sensorimotor gating, in schizophrenia, 536
Sensory cortex
in attention-deficit/hyperactivity disorder, 48
Serotonin
catabolism of, 334
gamma-aminobutyric acid and, in psychosis pathophysiology, 128
genetically driven variation in function of, 888
toxicity of, 1046
Serotonin 1A receptor
altered binding of, in major depression, 106
Serotonin 2A receptors
binding, aggression and, 235
description of, 1071
Serotonin 1B receptor gene
inattentive subtype of attention-deficit/hyperactivity disorder and, 106
Serotonin receptor intron 2 variant
suicide completion in major depression and, 114
Serotonin syndrome, 1046
Serotonin transporter
availability, during antidepressant treatment, 301
[^{11}C]DASB binding of, 821
diencephalon, in major depression, 40
occupancy studies of, 821
polymorphism of
gene by environment interactions, 224
social adversity and, 224
sertraline occupancy of, 821

venlafaxine effects on, 408
Serotonin transporter gene
aggressive behavior and, family-based association test of, 836
brain-derived neurotrophic factor and, in childhood depression, 673
variant of, 888
Serotonin$_{2C}$ receptors
clozapine effects on, 568
haloperidol effects on, 568
Serotonin–norepinephrine reuptake inhibitors
bupropion used with, 203
Sertraline, 821
Sex
diencephalon serotonin transporter availability in major depression associated with, 40
striatal dopamine release differences based on, 966
Sialyltransferase 8B gene polymorphisms, 652
Sleep
cortisol levels, in affective disorders, 24
Smoking
alcohol and illicit drug use and, in attention-deficit/hyperactivity disorder youth, 258
ethanol dependence attenuated by, 85
Smooth pursuit eye movement, 754
Sociability
genetic analysis of, using mouse model system, 415
Social adversity
serotonin transporter polymorphism and, 224
Social anxiety
amygdala hyperactivity to harsh faces correlated with severity of, 424
public speaking-related, 664
startle reactivity and, relationship between, 664
Social phobia
amygdala hyperactivity to harsh faces correlated with severity of, 424
Soluble amyloid precursor protein, 858
Spatial reference memory, 1219
Specific phobia
phobogenic stimuli in, 162
Startle, fear-potentiated, 872
Startle reactivity
social anxiety and, relationship between, 664
Stress. *See also* Posttraumatic stress disorder
chronic
cardiovascular changes induced by, fluoxetine's effects on, 309
hippocampal structure and function affected by, 244
cortisol administration before exposure to, 1208
early life, anterior cingulate morphometry affected by, 975
fear conditioning modulated by, 516
hippocampal neurogenesis regulated by, 1136
mood disorders related to, neurotrophic model for, 1116
during pregnancy, effects on maternal care, 1227
prenatal, hippocampal neurogenesis deficits caused by, 786
Striatal dopamine release
sex differences in, 966
Stroop task, 958
Substance abuse
methylphenidate treatment and, 635
semantic priming after ketamine use, 265
Substance P
aprepitant antagonism of, 216
Suicide
aggression and 5-HT$_{2A}$ receptor binding in, 235
antidepressants and, 1021
arginine vasopressin levels after, 594
corticotropin-releasing hormone levels after, 594
gastrin-releasing peptide levels after, 594
in major depression patients, 114
neuromedin B alterations in, 594
neuropeptide changes associated with, 594
serotonin receptor intron 2 variant and, 114
Synaptic plasticity, in schizophrenia, 929

Temporal lobe epilepsy
interictal psychosis and, magnetization transfer imaging study of, 560
Testosterone, 872
Threat-relevant cues, 816
Transcranial magnetic stimulation
repetitive, for medication-resistant major depression, 187
Transient receptor potential vanilloid 1 receptors, 508
Treatment algorithms, for depression, 1029
Treatment effects, 990
Tricyclic antidepressants
placental passage of, 287
serotonin toxicity and, 1046
Tryptophan depletion, effects on obsessive-compulsive disorder core symptoms, 853
Tryptophan hydroxylase 1 gene variants
haplotype analysis of, in major depression, 295
Tumor necrosis factor-α signaling, 775
Turner syndrome
magnetic resonance imaging of, 273
proton magnetic resonance spectroscopy of, 273
22q11 deletion syndrome, 1172

Unipolar depression
cingulate volumes in, 702
cortical inefficiency in, 958
cortical inhibition impairments in, 395

Val^{66}met allele, 812
Venlafaxine
norepinephrine transporter affected by, 408
serotonin transporter affected by, 408
Ventral nucleus accumbens shell, 1236
Ventral prefrontal cortex
in bipolar disorder, 611
Ventral tegmental area
in depression, 1151
dopamine neurons, methylphenidate effects on, 635

White matter
in autism, 1
degeneration of, in alcoholism, 364
Women
prefrontal cortex and limbic/paralimbic system activation secondary to body image distortions by, 380

X chromosome
brain development influenced by, 273

Volume Contents

Volume 59, Number 1, January 1, 2006

Original Articles

1 **Cortical Gray and White Brain Tissue Volume in Adolescents and Adults with Autism**
Heather Cody Hazlett, Michele D. Poe, Guido Gerig, Rachel Gimpel Smith, and Joseph Piven

7 **Neural Correlates of Executive Function in Autistic Spectrum Disorders**
Nicole Schmitz, Katya Rubia, Eileen Daly, Anna Smith, Steve Williams, and Declan G.M. Murphy

17 **Two Different Putative Genetic Animal Models of Childhood Depression**
Oz Malkesman, Yoram Braw, Rachel Maayan, Abraham Weizman, David H. Overstreet, Meytal Shabat-Simon, Yael Kesner, Daphna Touati-Werner, Gal Yadid, and Aron Weller

24 **Peri-Sleep-Onset Cortisol Levels in Children and Adolescents with Affective Disorders**
Erika E. Forbes, Douglas E. Williamson, Neal D. Ryan, Boris Birmaher, David A. Axelson, and Ronald E. Dahl

31 **Explicit and Implicit Facial Affect Recognition in Manic and Depressed States of Bipolar Disorder: A Functional Magnetic Resonance Imaging Study**
Chi-Hua Chen, Belinda Lennox, Rebecca Jacob, Andrew Calder, Vicky Lupson, Ruth Bisbrown-Chippendale, John Suckling, and Ed Bullmore

40 **Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression**
Julie K. Staley, Gerard Sanacora, Gilles Tamagnan, Paul K. Maciejewski, Robert T. Malison, Robert M. Berman, Meena Vythilingam, Akira Kugaya, Ronald M. Baldwin, John P. Seibyl, Dennis Charney, and Robert B. Innis

48 **Atypical Motor and Sensory Cortex Activation in Attention-Deficit/Hyperactivity Disorder: A Functional Magnetic Resonance Imaging Study of Simple Sequential Finger Tapping**
Stewart H. Mostofsky, Sheryl L. Rimrodt, Joanna G.B. Schafer, Avery Boyce, Melissa C. Goldberg, James J. Pekar, and Martha B. Denckla

57 **Brain Structure in Preclinical Huntington's Disease**
Jane S. Paulsen, Vince A. Magnotta, Ania E. Mikos, Henry L. Paulson, Elizabeth Penziner, Nancy C. Andreasen, and Peg C. Nopoulos

64 **ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice**
Nancy Pavón, Ana B. Martín, Ainhoa Mendialdua, and Rosario Moratalla

75 **Repeated Methamphetamine Treatment Impairs Recognition Memory Through a Failure of Novelty-Induced ERK1/2 Activation in the Prefrontal Cortex of Mice**
Hiroyuki Kamei, Taku Nagai, Hiroko Nakano, Yuriko Togan, Masanori Takayanagi, Kenji Takahashi, Kana Kobayashi, Shigeru Yoshida, Kenji Maeda, Kazuhiro Takuma, Toshitaka Nabeshima, and Kiyofumi Yamada

85 **Cortical Gamma-Aminobutyric Acid Levels and the Recovery from Ethanol Dependence: Preliminary Evidence of Modification by Cigarette Smoking**
Graeme F. Mason, Ismene L. Petrakis, Robin A. de Graaf, Ralitza Gueorguieva, Elizabeth Guidone, Vladimir Coric, C. Neill Epperson, Douglas L. Rothman, and John H. Krystal

On the Internet

94 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 2, January 15, 2006

ORIGINAL ARTICLES

97 **Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis**
Richard S.E. Keefe, Larry J. Seidman, Bruce K. Christensen, Robert M. Hamer, Tonmoy Sharma, Margriet M. Sitskoorn, Stephanie L. Rock, Sandra Woolson, Mauricio Tohen, Gary D. Tollefson, Todd M. Sanger, and Jeffrey A. Lieberman, for the HGDH Research Group

106 **Altered Serotonin 1A Binding in Major Depression: A [carbonyl-C-11]WAY100635 Positron Emission Tomography Study**
Ramin V. Parsey, Maria A. Oquendo, R. Todd Ogden, Doreen M. Olvet, Norman Simpson, Yung-yu Huang, Ronald L. Van Heertum, Victoria Arango, and J. John Mann

114 **STin2 Variant and Family History of Suicide as Significant Predictors of Suicide Completion in Major Depression**
Catalina Lopez de Lara, Alexandre Dumais, Guy Rouleau, Alain Lesage, Mimi Dumont, Nadia Chawky, Martin Alda, Chawki Benkelfat, and Gustavo Turecki

121 **Role of Monoamine Oxidase A Genotype and Psychosocial Factors in Male Adolescent Criminal Activity**
Kent W. Nilsson, Rickard L. Sjöberg, Mattias Damberg, Jerzy Leppert, John Öhrvik, Per Olof Alm, Leif Lindström, and Lars Oreland

128 **γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation**
Deepak Cyril D'Souza, Roberto B. Gil, Edward Zuzarte, Lisa M. MacDougall, Lia Donahue, John S. Ebersole, Nashaat N. Boutros, Tom Cooper, John Seibyl, and John H. Krystal

138 **Impaired Recruitment of the Dorsolateral Prefrontal Cortex and Hippocampus During Encoding in Bipolar Disorder**
Thilo Deckersbach, Darin D. Dougherty, Cary Savage, Stephanie McMurrich, Alan J. Fischman, Andrew Nierenberg, Gary Sachs, and Scott L. Rauch

147 **Impact of Selenium on Mood and Quality of Life: A Randomized, Controlled Trial**
Margaret Rayman, Alexander Thompson, Margaret Warren-Perry, Rachel Galassini, Janet Catterick, Emma Hall, David Lawrence, and Judith Bliss

155 **Cognitive Dysfunction, Hippocampal Atrophy and Glucocorticoid Feedback in Alzheimer's Disease**
Eva Elgh, Ann Lindqvist Åstot, Markku Fagerlund, Sture Eriksson, Tommy Olsson, and Birgitta Näsman

162 **Neural Mechanisms of Automatic and Direct Processing of Phobogenic Stimuli in Specific Phobia**
Thomas Straube, Hans-Joachim Mentzel, and Wolfgang H.R. Miltner

171 **Cortisol, Learning, Memory, and Attention in Relation to Smaller Hippocampal Volume in Police Officers with Posttraumatic Stress Disorder**
Ramón J.L. Lindauer, Miranda Olff, Els P.M. van Meijel, Ingrid V.E. Carlier, and Berthold P.R. Gersons

178 **Corticosterone-Induced Inhibition of Gliogenesis in Rat Hippocampus is Counteracted by Electroconvulsive Seizures**
Malin Wennström, Johan Hellsten, Joakim Ekstrand, Hanna Lindgren, and Anders Tingström

187 **A Controlled Study of Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Major Depression**
David H. Avery, Paul E. Holtzheimer III, Walid Fawaz, Joan Russo, John Neumaier, David L. Dunner, David R. Haynor, Keith H. Claypoole, Chandra Wajdik, and Peter Roy-Byrne

Brief Report

195 **Failure to Confirm Allelic Association Between Markers at the CAPON Gene Locus and Schizophrenia in a British Sample**
Vinay Puri, Andrew McQuillin, Srinivasa Thirumalai, Jacob Lawrence, Robert Krasucki, Khalid Choudhury, Susmita Datta, Simon Kerwin, Digby Quested, Nicholas Bass, Jonathan Pimm, Graham Lamb, Helen Moorey, Gomathinayagam Kandasami, Allison Badacsonyi, Katie Kelly, Jenny Morgan, Bhaskar Punukollu, Haitham Nadeem, David Curtis, and Hugh M.D. Gurling

On the Internet

198 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 3, February 1, 2006

Review

203 **Use of Bupropion in Combination with Serotonin Reuptake Inhibitors**
Sidney Zisook, A. John Rush, Barbara R. Haight, Dawn C. Clines, and Carol B. Rockett

Original Articles

211 **Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study**
Mark H. Pollack, Naomi M. Simon, Alyson K. Zalta, John J. Worthington, Elizabeth A. Hoge, Eric Mick, Gustavo Kinrys, and Julia Oppenheimer

216 **Lack of Efficacy of the Substance P (Neurokinin$_1$ Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder**
Martin Keller, Stuart Montgomery, William Ball, Mary Morrison, Duane Snavely, Guanghan Liu, Richard Hargreaves, Jarmo Hietala, Christopher Lines, Katherine Beebe, and Scott Reines

224 **Social Adversity, the Serotonin Transporter (5-HTTLPR) Polymorphism and Major Depressive Disorder**
Paul G Surtees, Nicholas WJ Wainwright, Saffron AG Willis-Owen, Robert Luben, Nicholas E Day, and Jonathan Flint

230 **D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia**
Guochuan E. Tsai, Pinchen Yang, Yue-Cune Chang, and Mian-Yoon Chong

235 **Higher Postmortem Prefrontal 5-HT$_{2A}$ Receptor Binding Correlates with Lifetime Aggression in Suicide**
Maria A. Oquendo, Stefani A. Russo, Mark D. Underwood, Suham A. Kassir, Steven P. Ellis, J. John Mann, and Victoria Arango

244 **Regulation of Hippocampal Gene Expression Is Conserved in Two Species Subjected to Different Stressors and Antidepressant Treatments**
Julieta Alfonso, Luciana R. Frick, Dafne M. Silberman, María L. Palumbo, Ana M. Genaro, and Alberto C. Frasch

252 **Pituitary Volume in Pediatric Obsessive-Compulsive Disorder**
Frank P. MacMaster, Aileen Russell, Yousha Mirza, Matcheri S. Keshavan, S. Preeya Banerjee, Rashmi Bhandari, Courtney Boyd, Michelle Lynch, Michelle Rose, Jennifer Ivey, Gregory J. Moore, and David R. Rosenberg

258 **Is Cigarette Smoking a Gateway to Alcohol and Illicit Drug Use Disorders? A Study of Youths with and without Attention Deficit Hyperactivity Disorder**
Joseph Biederman, Michael C. Monuteaux, Eric Mick, Timothy E. Wilens, Jessie A. Fontanella, Katrina M. Poetzl, Taralee Kirk, Joshua Masse, and Stephen V. Faraone

265 **Semantic Priming after Ketamine Acutely in Healthy Volunteers and Following Chronic Self-Administration in Substance Users**
Celia J.A. Morgan, Susan L. Rossell, Fiona Pepper, James Smart, James Blackburn, Brigitta Brandner, and H. Valerie Curran

273 **Influence of X Chromosome and Hormones on Human Brain Development: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study of Turner Syndrome**
William J. Cutter, Eileen M. Daly, Dene M.W. Robertson, Xavier A. Chitnis, Therese A.M.J. van Amelsvoort, Andrew Simmons, Virginia W.K. Ng, Benjamin S. Williams, Phillip Shaw, Gerard S. Conway, David H. Skuse, David A. Collier, Michael Craig, and Declan G.M. Murphy

Brief Reports

284 **Cortical γ-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy**
Gerard Sanacora, Lisa R. Fenton, Madonna K. Fasula, Douglas L. Rothman, Yael Levin, John H. Krystal, and Graeme F. Mason

287 **Placental Passage of Tricyclic Antidepressants**
Ada M. Loughhead, Zachary N. Stowe, D. Jeffrey Newport, James C. Ritchie, C. Lindsay DeVane, and Michael J. Owens

291 **Normal Brain Tissue Volumes after Long-Term Recovery in Anorexia and Bulimia Nervosa**
Angela Wagner, Phil Greer, Ursula F. Bailer, Guido K. Frank, Shannan E. Henry, Karen Putnam, Carolyn C. Meltzer, Scott K. Ziolko, Jessica Hoge, Claire McConaha, and Walter H. Kaye

Volume 59, Number 4, February 15, 2006

Original Articles

295 **Haplotype Analysis Reveals Tryptophan Hydroxylase (TPH) 1 Gene Variants Associated with Major Depression**
Rinat Gizatullin, Ghazal Zaboli, Erik G. Jönsson, Marie Åsberg, and Rosario Leopardi

301 **Serotonin Transporter Residual Availability During Long-Term Antidepressant Therapy Does Not Differentiate Responder and Nonresponder Unipolar Patients**
Jonathan Cavanagh, James Patterson, Sally Pimlott, Deborah Dewar, Jos Eersels, Mary Frances Dempsey, and David Wyper

309 **The Effects of Chronic Fluoxetine Treatment on Chronic Mild Stress-Induced Cardiovascular Changes and Anhedonia**
Angela J. Grippo, Terry G. Beltz, Robert M. Weiss, and Alan Kim Johnson

317 **Monocyte-Derived Dendritic Cells in Bipolar Disorder**
Esther M. Knijff, Cindy Ruwhof, Harm J. de Wit, Ralph W. Kupka, Ronald Vonk, Grard W. Akkerhuis, Willem A. Nolen, and Hemmo A. Drexhage

327 **Magnesium (Mg) Retention and Mood Effects After Intravenous Mg Infusion in Premenstrual Dysphoric Disorder**
Khursheed Khine, Donald L. Rosenstein, Ronald J. Elin, Julie E. Niemela, Peter J. Schmidt, and David R. Rubinow

334 **Monoamine Oxidase-A Genetic Variations Influence Brain Activity Associated with Inhibitory Control: New Insight into the Neural Correlates of Impulsivity**
Luca Passamonti, Francesco Fera, Angela Magariello, Antonio Cerasa, Maria Cecilia Gioia, Maria Muglia, Giuseppe Nicoletti, Olivier Gallo, Leandro Provinciali, and Aldo Quattrone

341 **Neurological Abnormalities in Schizophrenic Twins**
Marco M. Picchioni, Timothea Toulopoulou, Sabine Landau, Nadia Davies, Tracy Ribchester, and Robin M. Murray

349 **Quantitative Craniofacial Anomalies in a Racially Mixed Schizophrenia Sample**
Anne-Marie Donovan-Lepore, Judith Jaeger, Pál Czobor, Sherif Abdelmessih, and Stefanie M. Berns

354 **Brain-Derived Neurotrophic Factor and Autoantibodies to Neural Antigens in Sera of Children with Autistic Spectrum Disorders, Landau-Kleffner Syndrome, and Epilepsy**
Anne M. Connolly, Michael Chez, Elizabeth M. Streif, Richard M. Keeling, Paul T. Golumbek, Jennifer M. Kwon, James J. Riviello, Ricki G. Robinson, Rosalind J. Neuman, and Ruth Mary K. Deuel

364 **Supratentorial Profile of White Matter Microstructural Integrity in Recovering Alcoholic Men and Women**
Adolf Pfefferbaum, Elfar Adalsteinsson, and Edith V. Sullivan

373 **Shifting-Related Brain Magnetic Activity in Attention-Deficit/Hyperactivity Disorder**
Fernando Mulas, Almudena Capilla, Santiago Fernández, Máximo C. Etchepareborda, Pablo Campo, Fernando Maestú, Alberto Fernández, F. Xavier Castellanos, and Tomás Ortiz

380 **Distorted Images of One's Own Body Activates the Prefrontal Cortex and Limbic/Paralimbic System in Young Women: A Functional Magnetic Resonance Imaging Study**
Mitsuhaya Kurosaki, Naoko Shirao, Hidehisa Yamashita, Yasumasa Okamoto, and Shigeto Yamawaki

On the Internet

387 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 5, March 1, 2006

Priority Communication

389 **High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [^{11}C]-(+)-PHNO**
Matthäus Willeit, Nathalie Ginovart, Shitij Kapur, Sylvain Houle, Doug Hussey, Philip Seeman, and Alan A. Wilson

Original Articles

395 **Evidence for Impaired Cortical Inhibition in Patients with Unipolar Major Depression**
Malek Bajbouj, Sarah H. Lisanby, Undine E. Lang, Heidi Danker-Hopfe, Isabella Heuser, and Peter Neu

401 **Chronic Carbamazepine Decreases the Incorporation Rate and Turnover of Arachidonic Acid but Not Docosahexaenoic Acid in Brain Phospholipids of the Unanesthetized Rat: Relevance to Bipolar Disorder**
Richard P. Bazinet, Jagadeesh S. Rao, Lisa Chang, Stanley I. Rapoport, and Ho-Joo Lee

408 **A Comparison of the Chronic Treatment Effects of Venlafaxine and Other Antidepressants on Serotonin and Norepinephrine Transporters**
Georgianna G. Gould, Alfonso V. Altamirano, Martin A. Javors, and Alan Frazer

415 **A Mouse Model System for Genetic Analysis of Sociability: C57BL/6J Versus BALB/cJ Inbred Mouse Strains**
Geena Mary V. Sankoorikal, Kristin A. Kaercher, Catherine J. Boon, Jin Kyoung Lee, and Edward S. Brodkin

424 **Association between Amygdala Hyperactivity to Harsh Faces and Severity of Social Anxiety in Generalized Social Phobia**
K. Luan Phan, Daniel A. Fitzgerald, Pradeep J. Nathan, and Manuel E. Tancer

430 **Apoptosis Detected in the Amygdala Following Myocardial Infarction in the Rat**
Boubacar Pasto Wann, Matthieu Boucher, Sevan Kaloustian, Satra Nim, Roger Godbout, and Guy Rousseau

434 **A Polymorphism in the PDLIM5 Gene Associated with Gene Expression and Schizophrenia**
Yasue Horiuchi, Makoto Arai, Kazuhiro Niizato, Shyuji Iritani, Emiko Noguchi, Tsuyuka Ohtsuki, Minori Koga, Tadafumi Kato, Masanari Itokawa, and Tadao Arinami

440 **Hypericum Extract Reverses S-Ketamine-Induced Changes in Auditory Evoked Potentials in Humans – Possible Implications for the Treatment of Schizophrenia**
Harald Murck, Heidi Spitznagel, Michael Ploch, Klaus Seibel, and Klaus Schaffler

446 **Forward and Backward Visual Masking in Unaffected Siblings of Schizophrenic Patients**
Michael F. Green, Keith H. Nuechterlein, Bruno Breitmeyer, and Jim Mintz

452 **Abnormal Object Recall and Anterior Cingulate Overactivation Correlate with Formal Thought Disorder in Schizophrenia**
Michal Assaf, Paul R. Rivkin, Cheedem H. Kuzu, Vince D. Calhoun, Michael A. Kraut, Karyn M. Groth, Michael A. Yassa, John Hart Jr. and Godfrey D. Pearlson

460 **Association Between the 5HT1B Receptor Gene (*HTR1B*) and the Inattentive Subtype of ADHD**
Jordan W. Smoller, Joseph Biederman, Lori Arbeitman, Alysa E. Doyle, Jes Fagerness, Roy H. Perlis, Pamela Sklar, and Stephen V. Faraone

468 **Postnatal Loss of Methyl-CpG Binding Protein 2 in the Forebrain is Sufficient to Mediate Behavioral Aspects of Rett Syndrome in Mice**
Terry Gemelli, Olivier Berton, Erika D. Nelson, Linda I. Perrotti, Rudolf Jaenisch, and Lisa M. Monteggia

477 **Severe Deficit in Brain Reward Function Associated with Fentanyl Withdrawal in Rats**
Adrie W. Bruijnzeel, Ben Lewis, Lakshmi K. Bajpai, Timothy E. Morey, Donn M. Dennis, and Mark Gold

On the Internet

481 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 6, March 15, 2006

Original Articles

483 **Determining the Duration of Antidepressant Treatment: Application of Signal Detection Methodology and the Need for Duration Adaptive Designs (DAD)**
Harold A. Sackeim, Steven P. Roose, and Philip W. Lavori

493 **An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report**
A. John Rush, Ira H. Bernstein, Madhukar H. Trivedi, Thomas J. Carmody, Stephen Wisniewski, James C. Mundt, Kathy Shores-Wilson, Melanie M. Biggs, Ada Woo, Andrew A. Nierenberg, and Maurizio Fava

502 **Light Therapy for Seasonal Affective Disorder with Blue Narrow-Band Light-Emitting Diodes (LEDs)**
Gena Glickman, Brenda Byrne, Carissa Pineda, Walter W. Hauck, and George C. Brainard

508 **Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications**
Eleni T. Tzavara, Dominic L. Li, Larissa Moutsimilli, Tiziana Bisogno, Vincenzo Di Marzo, Lee A. Phebus, George G. Nomikos, and Bruno Giros

516 **Stress Differentially Modulates Fear Conditioning in Healthy Men and Women**
Eric D. Jackson, Jessica D. Payne, Lynn Nadel, and W. Jake Jacobs

523 **Segmented Hippocampal Volume in Children and Adolescents with Posttraumatic Stress Disorder**
Larry A. Tupler and Michael D. De Bellis

530 **Brain Activation During Antisaccades in Unaffected Relatives of Schizophrenic Patients**
Mathijs Raemaekers, Nick F. Ramsey, Matthijs Vink, Martin P. van den Heuvel, and Rene S. Kahn

536 **Sensorimotor Gating and Habituation of the Startle Response in Schizophrenic Patients Randomly Treated With Amisulpride or Olanzapine**
Boris B. Quednow, Michael Wagner, Jens Westheide, Katrin Beckmann, Niclaas Bliesener, Wolfgang Maier, and Kai-Uwe Kühn

546 **Immune Activation During Pregnancy in Mice Leads to Dopaminergic Hyperfunction and Cognitive Impairment in the Offspring: A Neurodevelopmental Animal Model of Schizophrenia**
Kimiyoshi Ozawa, Kenji Hashimoto, Takashi Kishimoto, Eiji Shimizu, Hiroshi Ishikura, and Masaomi Iyo

555 **Effects of Background and Prepulse Characteristics on Prepulse Inhibition and Facilitation: Implications for Neuropsychiatric Research**
Ming H. Hsieh, Neal R. Swerdlow, and David L. Braff

560 **A Magnetization Transfer Imaging Study in Patients with Temporal Lobe Epilepsy and Interictal Psychosis**
Dominique Flügel, Mara Cercignani, Mark R. Symms, Matthias J. Koepp, and Jacqueline Foong

568 **Clozapine and Haloperidol Differentially Alter the Constitutive Activity of Central Serotonin$_{2C}$ Receptors In Vivo**
Sylvia Navailles, Philippe De Deurwaerdère, and Umberto Spampinato

On the Internet

576 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 7, April 1, 2006

Original Articles

577 **Daytime Prazosin Reduces Psychological Distress to Trauma Specific Cues in Civilian Trauma Posttraumatic Stress Disorder**
Fletcher B. Taylor, Kathleen Lowe, Charles Thompson, Miles M. McFall, Elaine R. Peskind, Evan D. Kanter, Nancy Allison, Judi Williams, Patti Martin, and Murray A. Raskind

582 **Decreased Anterior Cingulate Volume in Combat-Related PTSD**
Steven H. Woodward, Danny G. Kaloupek, Chris C. Streeter, Christelle Martinez, Marie Schaer, and Stephan Eliez

588 **Brainstem Correlates of Defensive States in Humans**
Johanna M.P. Baas, Jean Milstein, Meghan Donlevy, and Christian Grillon

594 **Corticotropin-Releasing Hormone, Arginine Vasopressin, Gastrin-Releasing Peptide, and Neuromedin B Alterations in Stress-Relevant Brain Regions of Suicides and Control Subjects**
Zul Merali, Pamela Kent, Lisheng Du, Pavel Hrdina, Miklos Palkovits, Gabor Faludi, Michael O. Poulter, Tania Bédard, and Hymie Anisman

603 **The Clinical Phenotypes of Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic-Distinction**
Gabriele Masi, Giulio Perugi, Cristina Toni, Stefania Millepiedi, Maria Mucci, Nicoletta Bertini, and Hagop S. Akiskal

611 **Age, Rapid-Cycling, and Pharmacotherapy Effects on Ventral Prefrontal Cortex in Bipolar Disorder: A Cross-Sectional Study**
Hilary P. Blumberg, John H. Krystal, Ravi Bansal, Andrés Martin, James Dziura, Kathleen Durkin, Laura Martin, Elizabeth Gerard, Dennis S. Charney, and Bradley S. Peterson

619 **Stimulation of Neurogenesis in the Hippocampus of the Adult Rat by Fluoxetine Requires Rhythmic Change in Corticosterone**
Guo-Jen Huang and Joe Herbert

625 **Event-Related Oscillations in Offspring of Alcoholics: Neurocognitive Disinhibition as a Risk for Alcoholism**
Chella Kamarajan, Bernice Porjesz, Kevin Jones, David Chorlian, Ajayan Padmanabhapillai, Madhavi Rangaswamy, Arthur Stimus, and Henri Begleiter

635 **Different Adaptations in Ventral Tegmental Area Dopamine Neurons in Control and Ethanol Exposed Rats After Methylphenidate Treatment**
Roh-Yu Shen and Kar-Chan Choong

643 **Dysfunctional Attentional Networks in Children with Attention Deficit/Hyperactivity Disorder: Evidence from an Event-Related Functional Magnetic Resonance Imaging Study**
Kerstin Konrad, Susanne Neufang, Charlotte Hanisch, Gereon R. Fink, and Beate Herpertz-Dahlmann

652 **Association Between Polymorphisms in the Promoter Region of the Sialyltransferase 8B (*SIAT8B*) Gene and Schizophrenia**
Makoto Arai, Kazuo Yamada, Tomoko Toyota, Nanako Obata, Seiichi Haga, Yuuki Yoshida, Kazuhiko Nakamura, Yoshio Minabe, Hiroshi Ujike, Ichiro Sora, Kazuhiko Ikeda, Norio Mori, Takeo Yoshikawa, and Masanari Itokawa

Brief Reports

660 **Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping**
Rachel Yehuda, Sarah Brand, and Ren-Kui Yang

664 **Anticipation of Public Speaking in Virtual Reality Reveals a Relationship Between Trait Social Anxiety and Startle Reactivity**
Brian R. Cornwell, Linda Johnson, Luciano Berardi, and Christian Grillon

667 **Cortisol, the Cortisol-Dehydroepiandrosterone Ratio, and Pro-Inflammatory Cytokines in Patients with Current Major Depressive Disorder Comorbid with Borderline Personality Disorder**
Kai G. Kahl, Susanne Bens, Kristin Ziegler, Sebastian Rudolf, Leif Dibbelt, Andreas Kordon, and Ulrich Schweiger

On the Internet

672 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 8, April 15, 2006

Priority Communication

673 **Brain-Derived Neurotrophic Factor–5-HTTLPR Gene Interactions and Environmental Modifiers of Depression in Children**
Joan Kaufman, Bao-Zhu Yang, Heather Douglas-Palumberi, Damion Grasso, Deborah Lipschitz, Shadi Houshyar, John H. Krystal, and Joel Gelernter

ORIGINAL ARTICLES

681 **Polymorphisms of the Glucocorticoid Receptor Gene and Major Depression**
Elisabeth F.C. van Rossum, Elisabeth B. Binder, Matthias Majer, Jan W. Koper, Marcus Ising, Sieglinde Modell, Daria Salyakina, Steven W.J. Lamberts, and Florian Holsboer

689 **Reduced Glucocorticoid Receptor α Expression in Mood Disorder Patients and First-Degree Relatives**
Toshio Matsubara, Hiromasa Funato, Ayumi Kobayashi, Masaaki Nobumoto, and Yoshifumi Watanabe

696 **Glucocorticoids and Relapse of Major Depression (Dexamethasone/Corticotropin-Releasing Hormone Test in Relation to Relapse of Major Depression)**
Bente C. Appelhof, Jochanan Huyser, Mijke Verweij, Jantien P. Brouwer, Richard van Dyck, Eric Fliers, Witte J.G. Hoogendijk, Jan G.P. Tijssen, Wilmar M. Wiersinga, and Aart H. Schene

702 **Smaller Cingulate Volumes in Unipolar Depressed Patients**
Sheila C. Caetano, Simerjit Kaur, Paolo Brambilla, Mark Nicoletti, John P. Hatch, Roberto B. Sassi, Alan G. Mallinger, Matcheri S. Keshavan, David J. Kupfer, Ellen Frank, and Jair C. Soares

707 **Prefrontal Cortex and Amygdala Volume in First Minor or Major Depressive Episode After Cancer Diagnosis**
Eisho Yoshikawa, Yutaka Matsuoka, Hidenori Yamasue, Masatoshi Inagaki, Tomohito Nakano, Tatsuo Akechi, Makoto Kobayakawa, Maiko Fujimori, Naoki Nakaya, Nobuya Akizuki, Shigeru Imoto, Koji Murakami, Kiyoto Kasai, and Yosuke Uchitomi

713 **Regulation of Editing and Expression of Glutamate α-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs**
Alessandro Barbon, Maurizio Popoli, Luca La Via, Stefania Moraschi, Ivan Vallini, Daniela Tardito, Ettore Tiraboschi, Laura Musazzi, Roberto Giambelli, Massimo Gennarelli, Giorgio Racagni, and Sergio Barlati

721 **A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities**
Dan Rujescu, Andreas Bender, Martin Keck, Annette M. Hartmann, Frauke Ohl, Hanna Raeder, Ina Giegling, Just Genius, Robert W. McCarley, Hans-Jürgen Möller, and Heinz Grunze

730 **Neuropsychological Performance Over Time in People at High Risk of Developing Schizophrenia and Controls**
Marie-Claire Whyte, Caroline Brett, Lesley K. Harrison, Majella Byrne, Patrick Miller, Stephen M. Lawrie, and Eve C. Johnstone

740 **Decreased Encoding Efficiency in Schizophrenia**
Tara A. Cairo, Todd S. Woodward, and Elton T.C. Ngan

747 **Significant Association Between the Genetic Variations in the 5′ End of the N-Methyl-D-Aspartate Receptor Subunit Gene *GRIN1* and Schizophrenia**
Xinzhi Zhao, Huafang Li, Yongyong Shi, Ruqi Tang, Wuyan Chen, Jixia Liu, Guoyin Feng, Jianguo Shi, Lijuan Yan, Huijun Liu, and Lin He

754 **Effects of Nicotine on Hippocampal and Cingulate Activity During Smooth Pursuit Eye Movement in Schizophrenia**
Jody Tanabe, Jason R. Tregellas, Laura F. Martin, and Robert Freedman

762 **Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia**
Daniel S.G. Umbricht, John A. Bates, Jeffrey A. Lieberman, John M. Kane, and Daniel C. Javitt

On the Internet

773 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 9, May 1, 2006

Original Articles

775 **TNFα Signaling in Depression and Anxiety: Behavioral Consequences of Individual Receptor Targeting**
Birgitte B. Simen, Catharine H. Duman, Arthur A. Simen, and Ronald S. Duman

786 **Postnatal Stimulation of the Pups Counteracts Prenatal Stress-Induced Deficits in Hippocampal Neurogenesis**
Valerie Lemaire, Stephanie Lamarque, Michel Le Moal, Pier-Vincenzo Piazza, and Djoher Nora Abrous

793 **Regional- and Age-Dependent Reduction in trkB Receptor Expression in the Hippocampus Is Associated with Altered Spine Morphologies**
Oliver von Bohlen und Halbach, Sonja Krause, Diego Medina, Carla Sciarretta, Liliana Minichiello, and Klaus Unsicker

801 **Opposing Influence of Basolateral Amygdala and Footshock Stimulation on Neurons of the Central Amygdala**
J. Amiel Rosenkranz, Deanne M. Buffalari, and Anthony A. Grace

812 **BDNF *Val*^{66}*Met* Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects**
Joshua A. Bueller, Macksood Aftab, Srijan Sen, Diana Gomez-Hassan, Margit Burmeister, and Jon-Kar Zubieta

816 **Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues**
Catherine J. Harmer, Clare E. Mackay, Catriona B. Reid, Philip J. Cowen, and Guy M. Goodwin

821 **Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [^{11}C]DASB and Positron Emission Tomography**
Ramin V. Parsey, Justine M. Kent, Maria A. Oquendo, Misty C. Richards, Mali Pratap, Thomas B. Cooper, Victoria Arango, and J. John Mann

829 **A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder**
Joseph Biederman, Eric Mick, Craig Surman, Robert Doyle, Paul Hammerness, Theresa Harpold, Stephanie Dunkel, Meghan Dougherty, Megan Aleardi, and Thomas Spencer

836 **Family-Based Association Test of the 5HTTLPR and Aggressive Behavior in a General Population Sample of Children**
Brett C. Haberstick, Andrew Smolen, and John K. Hewitt

844 **Induction of a Hyperanxious State by Antenatal Dexamethasone: A Case for Less Detrimental Natural Corticosteroids**
Mário Oliveira, João M. Bessa, Ana Mesquita, Hugo Tavares, André Carvalho, Rui Silva, José M. Pêgo, João J. Cerqueira, Joana A. Palha, Osborne F.X. Almeida, and Nuno Sousa

853 **Lack of Effects on Core Obsessive-Compulsive Symptoms of Tryptophan Depletion During Symptom Provocation in Remitted Obsessive-Compulsive Disorder Patients**
Alexandre Berney, Debbie Sookman, Marco Leyton, Simon N. Young, and Chawki Benkelfat

858 **Toward a Reliable Distinction Between Patients with Mild Cognitive Impairment and Alzheimer-Type Dementia Versus Major Depression**
Anke Post, Nibal Ackl, Monika Rücker, Yvonne Schreiber, Elisabeth B. Binder, Marcus Ising, Annette Sonntag, Florian Holsboer, and Osborne F.X. Almeida

863 **Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia**
Todd Lencz, Christopher W. Smith, Danielle McLaughlin, Andrea Auther, Emilie Nakayama, Lauren Hovey, and Barbara A. Cornblatt

Brief Report

872 **A Single Administration of Testosterone Reduces Fear-Potentiated Startle in Humans**
Erno J. Hermans, Peter Putman, Johanna M. Baas, Hans P. Koppeschaar, and Jack van Honk

On the Internet

875 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 10, May 15, 2006

Commentary

881 **Advancing the Boundaries of Molecular Imaging**
Belinda Seto, Alan McLaughlin, King Li, Anne Menkens, Daniel Sullivan, and Roderic Pettigrew

Reviews

883 **^{13}C Magnetic Resonance Spectroscopy Studies of Alterations in Glutamate Neurotransmission**
Jun Shen

888 **Imaging Genetics: Perspectives from Studies of Genetically Driven Variation in Serotonin Function and Corticolimbic Affective Processing**
Ahmad R. Hariri, Emily M. Drabant, and Daniel R. Weinberger

898 **Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function**
Vanessa L. Cropley, Masahiro Fujita, Robert B. Innis, and Pradeep J. Nathan

908 **Imaging in Parkinson's Disease: The Role of Monoamines in Behavior**
David J. Brooks and Paola Piccini

919 **The Role of Extrastriatal Dopamine D2 Receptors in Schizophrenia**
Hidehiko Takahashi, Makoto Higuchi, and Tetsuya Suhara

929 **Synaptic Plasticity and Dysconnection in Schizophrenia**
Klaas E. Stephan, Torsten Baldeweg, and Karl J. Friston

940 **Imaging and In Vivo Quantitation of β-Amyloid: An Exemplary Biomarker for Alzheimer's Disease?**
Lisa Nichols, Victor W. Pike, Lisheng Cai, and Robert B. Innis

Original Articles

948 **Language Processing and Human Voice Perception in Schizophrenia: A Functional Magnetic Resonance Imaging Study**
Michihiko Koeda, Hidehiko Takahashi, Noriaki Yahata, Masato Matsuura, Kunihiko Asai, Yoshiro Okubo, and Hiroshi Tanaka

958 **Cortical Inefficiency in Patients with Unipolar Depression: An Event-Related fMRI Study with the Stroop Task**
Gerd Wagner, Esther Sinsel, Thomas Sobanski, Sabine Köhler, Varvara Marinou, Hans-Joachim Mentzel, Heinrich Sauer, and Ralf G.M. Schlösser

966 **Sex Differences in Striatal Dopamine Release in Healthy Adults**
Cynthia A. Munro, Mary E. McCaul, Dean F. Wong, Lynn M. Oswald, Yun Zhou, James Brasic, Hiroto Kuwabara, Anil Kumar, Mohab Alexander, Weiguo Ye, and Gary S. Wand

975 **Early Life Stress and Morphometry of the Adult Anterior Cingulate Cortex and Caudate Nuclei**
Ronald A. Cohen, Stuart Grieve, Karin F. Hoth, Robert H. Paul, Lawrence Sweet, David Tate, John Gunstad, Laura Stroud, Jeanne McCaffery, Brian Hitsman, Raymond Niaura, C. Richard Clark, Alexander MacFarlane, Richard Bryant, Evian Gordon, and Leanne M. Williams

On the Internet

983 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 11, June 1, 2006

Editorial

989 **Special Issue on Therapeutics**
A. John Rush

Reviews

990 **Size of Treatment Effects and Their Importance to Clinical Research and Practice**
Helena Chmura Kraemer and David J. Kupfer

997 **Prevention of Missing Data in Clinical Research Studies**
Stephen R. Wisniewski, Andrew C. Leon, Michael W. Otto, and Madhukar H. Trivedi

1001 **Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology**
Andrew C. Leon, Craig H. Mallinckrodt, Christy Chuang-Stein, Donald G. Archibald, Graeme E. Archer, and Kevin Chartier

1006 **Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder**
Carlos A. Zarate, Jr., Jaskaran Singh, and Husseini K. Manji

1021 **Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions**
Roma A. Vasa, Anthony R. Carlino, and Daniel S. Pine

1029 **Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why? A Systematic Review**
Mazda Adli, Michael Bauer, and A. John Rush

1039 **Mechanisms of Action of Medicines for Schizophrenia and Bipolar Illness: Status and Limitations**
Edward M. Scolnick

1046 **A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action**
P. Ken Gillman

Original Articles

1052 **Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder**
Maurizio Fava, W. Vaughn McCall, Andrew Krystal, Thomas Wessel, Robert Rubens, Judy Caron, David Amato, and Thomas Roth

1061 **Recurrence in Bipolar I Disorder: A Post Hoc Analysis Excluding Relapses in Two Double-blind Maintenance Studies**
Joseph R. Calabrese, Joseph F. Goldberg, Terence A. Ketter, Trisha Suppes, Mark Frye, Robin White, Angela DeVeaugh-Geiss, and Thomas R. Thompson

1065 **ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study**
Timothy E. Wilens, Marleen H. Verlinden, Lenard A. Adler, Patricia J. Wozniak, and Scott A. West

1071 **Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial**
Michael Poyurovsky, Artashes Pashinian, Ronit Weizman, Camil Fuchs, and Abraham Weizman

1078 **Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder**
Hadine Joffe, Lee S. Cohen, Trisha Suppes, Wren L. McLaughlin, Philip Lavori, Judith M. Adams, Cindy H. Hwang, Janet E. Hall, and Gary S. Sachs

1087 **Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis**
Mounira Banasr, Amélie Soumier, Micheline Hery, Elisabeth Mocaër, and Annie Daszuta

On the Internet

1097 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**

Volume 59, Number 12, June 15, 2006

Editorial

1103 **Special Issue: Animal Models of Mood and Psychotic Disorders**
Eric J. Nestler

Reviews

1104 **Mice with Mutations in the HPA-System as Models for Symptoms of Depression**
Marianne B. Müller and Florian Holsboer

1116 **A Neurotrophic Model for Stress-Related Mood Disorders**
Ronald S. Duman and Lisa M. Monteggia

1128 **The Fibroblast Growth Factor System and Mood Disorders**
Cortney A. Turner, Huda Akil, Stanley J. Watson, and Simon J. Evans

1136 **Hippocampal Neurogenesis: Regulation by Stress and Antidepressants**
Alex Dranovsky and René Hen

1144 **The Role of CREB in Depression and Antidepressant Treatment**
Julie A. Blendy

1151 **The Mesolimbic Dopamine Reward Circuit in Depression**
Eric J. Nestler and William A. Carlezon, Jr.

1160 **Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder**
Haim Einat and Husseini K. Manji

1172 **Mouse Models of 22q11 Deletion Syndrome**
Richard Paylor and Elizabeth Lindsay

1180 **Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models**
Jingshan Chen, Barbara K. Lipska, and Daniel R. Weinberger

1189 **A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions**
Koko Ishizuka, Matt Paek, Atsushi Kamiya, and Akira Sawa

1198 **Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?**
Craig M. Powell and Tsuyoshi Miyakawa

Original Articles

1208 **Blunted HPA Axis Response to Stress Influences Susceptibility to Posttraumatic Stress Response in Rats**
Hagit Cohen, Joseph Zohar, Yori Gidron, Michael A. Matar, Dana Belkind, Uri Loewenthal, Nitsan Kozlovsky, and Zeev Kaplan

1219 **3,4-Methylenedioxymethamphetamine in Adult Rats Produces Deficits in Path Integration and Spatial Reference Memory**
Jessica A. Able, Gary A. Gudelsky, Charles V. Vorhees, and Michael T. Williams

1227 **Stress During Gestation Alters Postpartum Maternal Care and the Development of the Offspring in a Rodent Model**
Frances A. Champagne and Michael J. Meaney

Brief Report

1236 **Microinjection of the L-Type Calcium Channel Antagonist Diltiazem into the Ventral Nucleus Accumbens Shell Facilitates Cocaine-Induced Conditioned Place Preferences**
Elena H. Chartoff, Andrea M. Pliakas, and William A. Carlezon, Jr.

On the Internet

1240 **Full text or abstracts of the following articles, which are currently "in press" in *Biological Psychiatry*, are available on our website now...**